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Zusammenfassung 
 
Seit 1997 führt das Auftreten von hoch pathogenen aviären Influenza Viren (HPAIV) des H5-
Subtyps zu schweren Verlusten in der Geflügelindustrie und verursachte bislang über 500 
humane Infektionen mit über 60% Mortalität. In Europa zirkulieren H7-Subtyp HPAIV seit 
langem, allerdings mit niedriger Pathogenität für den Menschen. Gleichwohl könnte die 
Fähigkeit von Influenza Viren (IV) ihr segmentiertes Genom bei einer Doppelinfektion zu 
vermischen (reassortieren) zu neuen H7-Typ HPAIV mit neuen Eigenschaften führen, die 
evtl. eine Gefahr für den Menschen darstellen. Das NS-Segment, welches für das NS1- und 
NS2/NEP-Protein kodiert, teilt sich in zwei Alleltypen auf (Aund B). Es kann sowohl die anti-
virale Wirtsantwort beeinflussen und die zelluläre mRNA-Prozessierung hemmen, als auch 
die Translation viraler mRNA fördern. NS1 trägt zu erhöhter Virulenz und Änderung des 
Wirtsspektrums bei und es wurde berichtet, dass NS-Segmente von H5-Typ HPAIV, welche 
nach 1998 isoliert wurden, die Vermehrung humaner IV in Säugerzellen erhöhten können. 
Dennoch ist nicht klar, wie der NS-Alleltyp, der Subtyp und das Jahr der Isolation des 
parentalen Viruses das Wirtsspektrum, die Genom-Replikation/Transkription, die 
Virusvermehrung und Pathogenität einer H7-Typ Reassortante beeinflußt.  
Zur Beantwortung dieser wichtigen Fragen wurden mittels reverser Genetik verschiedene 
reassortante A/FPV/Rostock/34 (H7N1) HPAIV mit NS-Segmenten von aviären H5- und H7-
Typ IV-Stämme erstellt. Virologische Charakterisierung zeigte, daß die Wachstumskinetiken 
der reassortanten IV sich vom wild Typ FPV unterscheiden und davon abhängen, ob Säuger- 
oder Vogelzellen infiziert worden waren. Überraschender Weise waren die verschiedenen NS-
Segmente nicht nur für Änderungen der anti-viralen Wirtsantwort verantwortlich, sondern 
beeinflußten außerdem die virale Genom-Replikation/-Transkription und dessen intra-
zellulären Transport. Weitere Experimente demonstrierten, daß die Effekte auf die 
Akkumulation der viralen RNA-Species sowohl von den spezifischen NS-Segmenten 
abhingen, als auch von dem genetischen Hintergrund der Viruspolymerase. IFN-beta-
Expression und Apoptose-Induktion waren entgegengesetzt zur Virusvermehrung, wogegen 
das NS-Allel, der Virussubtyp und das Maß der NS1-Expression keine Korrelation zeigten. 
Obwohl es wahrscheinlich ist, dass die Vielzahl der Effekte von NS1 sich auf viele Virus- und 
Wirtsprozesse auswirken, wodurch es auch nicht möglich ist den wichtigsten Effekt für die 
Virusvermehrung zu definieren, zeigen diese Ergebnisse das der Ursprung des NS-Segments 
die Vermehrungseffizienz, das Wirtsspektrum und die Pathogenität von H7-Typ HPAIV 
beeinflussen kann.  
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Summary 
 
Since 1997 the emergence of H5-type highly pathogenic avian influenza virus (HPAIV) has 
resulted in major losses to the poultry industry and caused over 500 human infections with 
approximately 60% mortality. In Europe H7-type HPAIV have been circulating for a long 
time with very little pathogenicity for humans. Nevertheless, the ability of influenza viruses 
(IV) to mix their segmented genomes upon double infections could lead to the emergence of 
new, reassortant H7-type HPAIV with altered characteristics that could pose an additional 
threat to humans. The viral NS segments encoding the NS1 and NS2/NEP proteins can affect 
the anti-viral host responses, inhibit cellular mRNA processing and enhance viral mRNA 
translation. NS1 contributes to high virulence and host range variation and it was reported that 
NS segments of H5-type HPAIV isolated after 1998 can enhance replication of human IV 
reassortants in mammalian cells. Still it is not clear how the NS allele type, the subtype and 
the year of isolation of the parental virus affects host range, genome replication/transcription, 
viral propagation and pathogenicity of an H7-type reassortant. 
In order to elucidate several of these important questions reassortant A/FPV/Rostock/34 
(H7N1) HAPIV with NS segments from H5- and H7-type avian IV strains were generated by 
reverse genetics. Virological characterizations demonstrated that growth kinetics of the 
reassortant viruses differed from the wild type FPV and depended on the mammalian or avian 
origin of the infected cells. Surprisingly, the different reassortant NS segments were not only 
responsible for alterations in the anti-viral host response, but furthermore affected viral 
genome replication/transcription and its intra-cellular transport. Further experiments 
demonstrated that the effects on accumulation of viral RNA species depended on the specific 
NS-segment as well as on the genetic background of the viral polymerase. IFN-beta 
expression and apoptosis induction were found to be inversely correlated to viral growth, 
while the NS allele, virus subtype and NS1 protein expression levels showed no correlation. 
Even though it is likely that the multiple effects of the NS1 protein act on many viral and host 
processes as why one can not conclude which of the effects is the most important for the viral 
replication ability, these results demonstrate that the origin of NS segment can affect the 
replication efficiency, host range and pathogenicity of H7-type HPAIV.  
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1. Introduction 
1.1. Influenza viruses 
1.1.1. Classification of influenza viruses 
The Orthomyxoviridae family is divided into five genera: Influenza A virus (IAV), Influenza 
B virus, Influenza C virus, Isavirus and Thogoto virus. Orthomyxo viruses are single-standed 
RNA viruses containing a linear segmented genome. For influenza viruses (IV), the number of 
RNA segments varies: eight for influenza A and B virus, seven for influenza C virus. The 
three genera of influenza (A; B; C) virus are classified by the characteristic of their 
nucleoprotein and matrix protein. Based on the antigenicity of their hemaggulutinin (HA) and 
neuraminidase (NA), IAV is further subdivided into 16 HA subtypes and 9 NA subtypes (1). 
For influenza B and C, they have not been subdivided into any subtype.  
IAV can infect birds and mammals. Wild aquatic birds are their natural reservoir in which 
they generally cause no apparent disease (2, 3). Influenza B viruses are normally found only 
in humans. Although influenza B viruses can cause human epidemics, they have not caused 
pandemics. Influenza C virus usually causes either a very mild respiratory illness or no 
symptoms at all; it does not cause epidemics or pandemics and it does not have the severe 
public health impact compared to influenza types A and B. 
  
1.1.2. Avian influenza virus (AIV) 
Usually, “avian influenza virus” (AIV) refers to influenza A virus found in birds, but 
infections with these viruses can occur to human occasionally. Wild birds carry AIV in their 
intestines so that AIV is shed and spread via feces, saliva and nasal secretions. Most species 
of wild birds infected with AIV usually do not get sick.  
Only IAV can infect birds. So far all subtypes (including 16 HA and 9 NA) of IAV have been 
found in aquatic birds (2). Based on the pathogenicity for chickens, AIV can be classified into 
lowly pathogenic avian influenza virus (LPAIV) and highly pathogenic avian influenza virus 
(HPAIV). LPAIV is the common form of virus found in wild birds. It usually causes limited 
infection and leads to only mild symptoms in domestic birds. However, HPAIV causes 
disease that affects multiple internal organs and has a mortality rate of as high as 100%. Only 
H5 and H7 subtypes  can become highly pathogenic and each of the highly pathogenic H5 and 
H7 lineages originated from non-pathogenic precursor viruses (4). So far, the AIV that have 
been transmitted from commercial poultry to humans are of subtypes H5, H7 and H9 (5).  
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1.1.3. Epidemiology of influenza viruses 
Every year, especially in the cold season, influenza can easily spread among human and often 
become epidemic or sometimes pandemic, resulting annually in thousands of deaths in 
millions in pandemic outbreak. Generally, an influenza outbreak normally reaches its peak 
around 2-3 weeks after its sudden beginning, and may last for 5-8 weeks (6). An influenza 
pandemic is a “flu” epidemic that involves almost all age groups of people in two or more 
continents (WHO). At least three pandemics occurred in the last century (Fig1.1). In 1918 (7), 
the pandemic was caused by a H1N1 virus and more than 20 millions people died. In 1957, a 
new pandemic subtype (H2N2) appeared in China, replaced the old H1N1 completely and 
spread quickly and world wide, resulting in a million of deaths (8). This H2N2 virus 
continued to cause epidemics until 1968 it was completely substituted by another pandemic 
subtype (H3N2) which originated from Hong Kong (9). In 1977, the subtype H1N1 
reappeared. Unlike the situation in 1957 and in 1968, the new H1N1 subtype didn’t eliminate 
the old H3N2 subtype. In addition, influenza B has been circulating in humans since 1940 
(10). Up to now, as Fig1.1 shows, the prevalent circulating IV are a mixture of H3N2, H1N1 
and influenza B. In 2009, a global flu pandemic outbreak caused by a new strain of H1N1 
influenza virus, often referred to colloquially as "swine flu",   which contains a combination 
of genes from swine, avian, and human IV (http://www.cdc.gov/H1N1flu /qa.htm). 
For a human influenza pandemic, there are three prerequisites: 1) emergence of a new IV 
subtype to which the population has little or no immunity and against which there is no 
effective vaccine; and 2) ability of IV to replicate in human beings and cause disease; and 3) 
the new IV can transmit from human to human. For example, the three pandemic stains H1N1 
(1918), H2N2 (1957) and H3N2 (1968) are believed to be reassortant viruses between human 
IV and avian influenza virus (AIV) which evolved during a coinfection in pigs. Pigs are 
recoginized as mixure vessels for the generation of reassort IV. Reassortant viruses may be 
introduced into a naïve human population and may cause new pandemics (11).  
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Fig. 1.1: Pandemics of influenza: Four worldwide (pandemic) outbreaks of influenza in the human populations 
have occurred since 1900: 1918 spanish flu (H1N1), 1957 Asian flu (H2N2), 1968 Hong Kong flu (H3N2) and 
2009 pandemic new H1N1 flu. Some notable epidemics although not classified as true pandemics occurred: one 
in 1889, one in 1990 and another one in 1977 that was a pandemic in children. (adapted and modified from Dr 
Masato Tashiro, Director, Centre for IV Research,  National Institute of Infectious Diseases (NIID), Japan)  
 
In Italy, avian infection was firstly recorded in 1878 and the disease was known as “fowl 
plague”. In 1902, the first documented IV was isolated from chicken. Since 1959 to 2000, 
primary outbreaks of HPAI in poultry (turkey and chicken) have been reported 17 times (eight 
since 1990). In each outbreak, millions of birds were slaughtered in order to control the 
outbreak (12). Of the hundreds of strains of AIV, only several are known to have caused 
human infections: H5N1, H7N2, H7N3, H7N7, and H9N2. In general, human infection with 
these viruses has resulted in mild symptoms and rarely with severe illness, with one notable 
exception: the highly pathogenic H5N1 virus. HPAIV attracted people’s concerns since 1997, 
when an H5N1 outbreak in Hong Kong was accompanied with 18 human infections resulting 
in 6 deaths. In March 2003, HPAIV H7N7 broke out in Netherlands and quickly spread to 
Belgium and Germany (13, 14). The virus infected 89 persons and caused conjunctivitis in 83 
persons, and one death (15). Other outbreaks of HPAIV H5N1 subtype happened again in 
Vietnam’s and Thailand’s poultry industry in the early 2004 accompanied with human cases 
(16). Since then, the virus has spread across Asia and into Europe, the Middle East, and 
Africa. Humans in close contact with sick poultry and on rare occasion with other infected 
humans have become infected. Until June 8th, 2010, 499 confirmed human cases caused by 
H5N1 with 295 deaths (59.1% mortality) were reported by the WHO (WHO: cumulative 
number of confirmed human cases of avian influenza A/(H5N1) reported to WHO). 
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1.1.4. Risk of influenza pandemics (cited from report  of CDC USA) 
As mentioned before, H5, H7 and H9 have caused outbreaks in birds and humans. Especially 
H5N1 has crossed host barrier to humans, and occasionally human-to-human cases have been 
observed in 2007 (17). More particular concerns about this H5N1 virus are: 1) domestic ducks 
can excrete large quantities of highly pathogenic virus without showing signs of illness, and 
are acting as a “silent” reservoir of the virus, perpetuating transmission to other birds (18). 2) 
When compared with H5N1 viruses from 1997 and early 2004, H5N1 viruses now circulating 
are more lethal to experimentally infected mice and to ferrets (a mammalian model) and 
survive longer in the environment. 3) H5N1 appears to have expanded its host range, infecting 
and killing mammalian species previously considered resistant to infection with avian 
influenza viruses. 4) The behavior of the virus in its natural reservoir, wild waterfowl, may be 
changing. The spring 2005 die-off of 6,000 migratory birds, caused by H5N1, was highly 
unusual. 
 
1.1.5. Morphology and structure of IAV 
IV particles are pleomorphic, they can be filamentous and spherical. The diameter of spherical 
particle ranges from 80nm to 120nm (19). IAV is an enveloped virus containing eight single 
stranded RNA segments of negative polarity. The lipid bilayer is derived from the plasma 
membrane of infected cells when viruses bud from cells. As Fig1.2 shows, two integral 
membrane glycoproteins HA and NA protrude from the virion surface. Matrix protein 2 (M2, 
ion channel protein) is also integrated and tanslocated into the membrance. Matrix protein 1 
(M1) underlies the lipid envelop and interacts with the NS2 protein. Within the envelope, the 
RNA-dependent RNA-polymerase (RdRp) subunits (PB2, PB1 and PA) and the nucleocapsid 
protein (NP), together with viral RNA segments, which differ in length from 890nt to 2341nt, 
constitute the ribonucleoprotein (RNP) complexes. The RNPs resemble into a twisted rod (10-
15nm in width and 30-120nm in length) that is folded back and coiled on itself (20). Eight rod 
like RNPs of different length surround a central segment, which may play a role in 
maintaining the integrity of the viral genome during repeated cycles of replication (20) .  
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Fig. 1.2: structure of the influenza virion. The eight viral RNA segments were separated by electrophoresis 
(left). The corresponding gene products and their localization within the virus particle are depicted on the right. 
The only non-structural virus protein, the NS1, is only found inside infected cells. (Adapted from Ludwig et 
al.(21)) 
 
Each of the eight RNA segments of IAV contains two highly conserved sequences: the first 12 
nt at the 3’ end and the last 13 nt at the 5’ end. The partially complementary 5’- and 3’ end of 
vRNA and cRNA, can form a “cork-screw” structure by intrastrand binding (22, 23), which 
acts as the promoter for the viral RNA replication (24). Most of viral genes encode at least 
one viral protein except the nonstructral (NS) gene and M gene which encode two proteins 
(table 1.1). The NS gene encodes two proteins: a 26k Da protein NS1 and a 14k Da protein 
NS2. NS2 is translated from spliced mRNA and shares the same AUG initiation codon and 
the first 10 aa with NS1 (25). The M gene can be transcribed into three mRNAs: the unspliced 
M1 mRNA, the other two alternative spliced mRNAs designated M2 and mRNA3, which 
differs in the 5’ spliced site. M2 protein also shares the AUG initiation codon and the 
subsequent eight amino acids with M1, whereas the product of mRNA3 (a nine amino acid 
peptide) is not found in vivo (26, 27). Some IAV PB1 genes can encode an 87aa PB1-F2 
protein(28), which is co-localized with the PB1 protein and may play a role in inducing 
cellular apoptosis (29) . The viral proteins are shown in the table 1.1. 
HA 
NA 
NP 
NA 
NP 
HA 
NS 
M 
PB2 
PB1 
PA 
NS1 
M1 
M2 
Segments 
NEP 
PB2 
PB1 
PA 
Gene - ProductsvRNA 
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Table 1.1: Influenza A virus proteins and functions (strain A/PR/8/34, H1N1) 
(Modified from Ludwig et al. (30)) 
Segment vRNA (nt) Protein AA Functions 
1 2341 PB2 759 subunit of  RDRP;  screening for cap sequence  
2 2341 PB1 
PB1-F2 
757 
87 
catalytic subunit of  RDRP; elongation 
Not encoded by all IAV, can induce apoptosis  
3 2233 PA 716 catalytic subunit of  RDRP, can cut the cap structure from cellular 
mRNA for viral RNA primers 
4 1778 HA 566 hemagglutinin; surface-glycoprotein;  
receptor binding; membrane fusion 
5 1565 NP 498 nucleoprotein; encapsidation of vRNA and cRNA; part of 
transcriptase complex; nuclear/cytoplasmic transport of vRNA 
6 1413 NA 454 neuraminidase; surface-glycoprotein;  
receptor disruption, virus releasing 
7 1027 M1 
M2 
252 
97 
matrix protein 
ion channel activity ; protecting HA-conformation 
8 890 NS1 
 
NEP/NS2 
230 
 
121 
post-transcription regulator; inhibition of (i) pre-mRMA splicing, 
(ii) polyadenylation (iii) PKR-activation 
nuclear export factor, regulation of trancription and replication  
 
1.2 Propagation and genome replication of IAV 
The replication cycle of IAV can be descripted in three steps (Fig1.3): 1) binding and 
uncoating; 2) replication and transcription; 3) virus assembling and budding.  
 
1.2.1. Binding and uncoating 
The HA protein of IAV can recognize and bind the sialyloligosaccharide receptor on the cell 
surface which contains α2,3- or α2,6-galactose sialic acid linkages. After binding, the attached 
virion undergoes endocytosis. The low pH in the late endocytic venicles triggers a 
conformational change in the cleaved-HA (see later) resulting in the insertion of HA2 fusion 
peptide into vesicle membrane. Meanwhile, under the low pH environment in the late 
endocytic venicles, the ion channel protein M2 permits protons flow into virion interior by 
simple diffusion, exposing the core to low pH. Low pH within the virions dissociates the 
interaction between the M1 and the RNPs.  The altered HA draws the virion membrane and 
cell membrane together and then the fusion takes place. RNPs are released into cell cytoplasm 
and then are imported into  the nucleus in an ATP-dependent manner (31). 
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Figure 1.3: Replication cycle of influenza virus. It starts when the HA-spike binds to its cellular receptor 
determinant on the cell surface. The virion is then taken into the cell through endocytosis. After the fusion 
between the viral and the endosomal membrane, the RNPs are released into the cell cytoplasm and transported 
into the nucleus, where transcription and replication of the viral RNA takes place. The viral mRNA is 
subsequently exported to the cytoplasm and translated into viral proteins. The replicative proteins like NP and 
polymerase proteins are transported back to the nucleus and continue the genome replication. The viral surface-
glycoprotein (e.g. HA and NA) are transported to the cell surface and modified by various post-translational 
processing. Late during virus replication cycle RNPs are exported out of the nucleus and packaged into new 
enveloped virions that are released from the membrane of infected cell through budding. (Adapted from S. 
Pleschka, Germany) 
 
1.2.2. Transcription and replication of viral genome 
The viral genome of IAV is replicated in the nucleus. Viral genomic RNA, the three 
polymerase subunits (PB2, PB1, and PA) and the nucleocapsidprotein (NP) form the viral 
Ribonucleoprotein complex (RNP), which is responsible for viral transcription and 
replication. PB1 and PA form a dimer in the cytoplasm, which is imported into the nucleus 
separately from PB2. Once in the nucleus, the PB1/PA dimer associates with PB2 to form the 
trimetric polymerase.(32). In the complex, the N terminus of the PB1 protein interacts with 
PB2, and the C terminus of PB1 interacts with PA (33, 34). The polymerase complex 
recognizes the influenza virus promoter structure in a sequence-specific manner (35, 36) and 
also interacts with NP (37). It is reported that only the PB1-PB2 or the PB1-PA complex have 
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transcriptase or replicase activity respectively (38-40), however, all three polymerase subunits 
maybe more efficient than the dimeric complexes for replication and transcription (41, 42). 
Recent studies suggested a new model of viral replication and transcription: a template RNP is 
replicated in trans by a soluble polymerase complex. A polymerase complex distinct from the 
replicative enzyme directs the encapsidation of progeny vRNA. In contrast, transcription of 
the vRNP would occur in cis and the resident polymerase complex is responsible for mRNA 
synthesis and polyadenylation (43). The initiation of influenza virus mRNA systhesis is 
primered by m7GpppXm-containing capped primers (10-13nt long), which are generated by 
the cellular RNA polymerase II. PB2 of the RNP complex recognizes 5’ primer of cellular 
mRNA and PA snatches the 5’ cap of cellular mRNA as primers for viral mRNAs (44, 45). 
Chain elongation of viral RNA is carried out by PB1 (34). Transcription stops when it reaches 
the polyA site which is 15–22nt away from the 5’ end of vRNA as shown in Fig 1.4.. 
Polyadenylation depends on three mechanisms: 1) viral vRNA contains a 5-7 Uridines-rich 
region located 15-22nt away from its 5’ end, which serves as the polyA signal (46-50). 2) the 
RNA duplex of the promoter structure; and specific nucleotides near the 5’ end of the vRNA 
(49). And 3) the binding of the polymerase complex to the promoter region serves as a 
physical barrier that causes reiterative copying at the neighbouring uridine stretch (24). After 
polyadenoylation, the viral mRNAs are transported into the cellular cytoplasm for translation 
by using the cellular translation machinery. After translation and post-translational 
modification, some of polymerase proteins (PB2, PB1 and PA), as well as NP, are transported 
back to nucleus for more replication and transcription. NP was found to bind new progeny 
vRNA and cRNA (complementary RNA) but not mRNA, and stabilizes the viral RNP (51), 
which is indispensable for viral replication in vivo. In the early infection, the synthesis of 
mRNAs encoding NP and NS1 dominates, later the production of mRNA for HA, NA and M1 
increases. While transcripts for polymerase proteins (PB2, PB1 and PA) are relatively low 
throughout the infection cycles, except at the earliest times (52).  
The viral cRNA was believed to be produced after the viral proteins had been synthesized. In 
this model, newly synthesized NP acts as a “switch” from transcription (mRNA) to replication 
(cRNA) by promoting the “read-through” at the ployA site and allowing the synthesis of 
cRNA, which in turn serves as the template to produce more vRNA (53, 54). However, equal 
quantities of cRNA are found to be synthesized through the infection cycles, which may 
indicate there is no regulation on cRNA production. If cRNA is produced early in infection, 
then the production of cRNA should increase. It was suggested that cRNA can be synthesized 
early, but may be degraded rapidly by cellular nucleases in the early infection, while 
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increasing amounts of polymerase proteins may protect the cRNA from degradation later in 
infection (55). The vRNA is replicated by cRNA intermediates into more vRNA and the 
amount of vRNA is increasing constantly during the infection.  
 
 
Figure 1.4: Replication and transcription of viral genome. The m7G cap of cellular mRNAs is recognized by 
PB2 and then cleaved by PA. The cap serves as a primer for viral mRNA synthesis carried out by PB1. The (-) 
sense vRNAs are directly transcribed into (+) sense mRNAs and replicated through producing (+) sense cRNAs 
intermediates to produce more vRNA molecules (Adapted from P. Digard,). 
 
After translation in the cytoplasm, viral membrane proteins (HA, NA and M2) are proceeding 
through the rough endoplasmic reticulum (rER) for oligomerization, and are then transported 
to Golgi apparatus for glycosylation and oligosaccharidation (56). After that, the mature 
glycoproteins HA and NA and the nonglycosylated M2 are transferred to the cellular 
membrane as a trimer (HA) and/or as tetramers (NA, M2). In the nucleus M1 bridges NEP to 
bind the PA of RNPs (57-61). And then the complexes are exported to the cytoplasm through 
the nuclear pore complex (NPC) by interaction with the cellular export factor CRM1 (62, 63). 
For further maturation (assembly) the M1 retains the RNPs in the cytoplasm (64). 
 
1.2.3. Virus assembling and budding (as reviewed in Nancy JC et al.(11))  
Viral core structures and the association of RNP with the plasma membrane have not been 
identified by electron microscopy in IV infected cells. RNP seems to associate with viral 
membrane proteins only when the virion starts building its shape (65). Virion incorporation 
signals are segment specific and have been identified on viral RNAs which promote their 
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efficient incorporation into virions (66-68). These signals are located in the non-coding 
regions at both ends of the vRNAs and extend into part of translated regions, thereby 
conferring segment specificity. Although influenza virus can accommodate more than eight 
viral segments (69) (a finding that suggested random incorporation of vRNAs) efficient 
packaging relies on cis-acting signals that govern the incorporation of the eight viral RNA 
segments into virions. The mechanism for selective vRNA incorporation remains to be 
determined. Presumably, RNP buds outward through the cell membrane. Substantial amounts 
of M1 are found in the cytoplasm throughout the infection period. M1 interacts with cellular 
membranes (70), and induces the formation of virus like particles (71, 72). Since at least a 
fraction of M1 is associated with RNPs in the virion, this protein possibly serves as molecular 
‘glue’, interacting with RNP on one hand and with HA, NA, or M2 on the other (61, 73). Such 
interactions may function as a budding signal (11). 
 
1.3. The pathogenecity and virulence of IAV 
The pathogenicity of influenza virus is a very complex phenomenon. On the molecular basis, 
the pathogenicity and virulence of influenza virus is determined by several interacting factors: 
1) the viral factors: the ability to mix the genome between two viruses due to the segmented 
genome of influenza virus (see later) (74), the ability to bind to the host cells, the replication 
efficiency and the ability to counteract the host immune response (75, 76) or viral mechanisms 
for stimulating a hyper-immune response; and 2) host factors, including the expression of 
different receptors on the host cells, the availability of a protease which is essential for HA 
cleavage (see later) and viral entry and the status of the host immune system. 
 
1.3.1 Viral glycoproteins 
Glycoproteins of IV play an important role in virulence and pathogenicity. As mentioned 
before, the HA protein binds to sialic acid (SA)–containing surface molecules on the host cell, 
and promotes the release of viral RNP complexes during infection into the cells through 
membrane fusion. In contrast, the sialidase activity of the neuraminidase (NA) protein 
removes SA to liberate new-born viruses from infected cells. The cleavage properties of HA 
and the distribution of infectivity-activating proteases in the host are important for virus 
tropism and the capacity of systemic spread. The HAs of HPAIV contain multiple amino acid 
(aa) basic residues at the cleavage site, and can be cleaved by ubiquitous intracellular 
proteases; while the HAs of all other IV contain only one aa R (Arginine) residue and can 
only be recognized by extracellular proteases limited to some respiratory and intestinal cells. 
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In addition, the specificity of HA can determine the host range. Human influenza viruses 
preferentially recognize sialyloligosacchrides containing SAα2,6Gal, matched by mainly 
NeuAcα2,6Gal linkages on the epithelial cells of the human trachea. In contrast, avian viruses 
preferentially recognize SAα2,3Gal sialyloligosacchrides, in accordance with the 
predominance of sialyoligosaccharides with NeuAcα2,3Gal linkages on the epithelial cells of 
avian intestine. High viral burdens are achieved when newly synthesized viruses are released 
from infected cells and then infect new cells (31). The NA glycoprotein removes SA from the 
cell surface of infected epithelial cells, which is necessary for the release of newly synthesized 
viruses. Thus, efficient virus replication involves balanced actions of both HA and NA 
antigens (77). It was reported that an avian virus with an N2 NA was introduced into the 
human population, and its SAα2,6 cleavage activity was increased, which suggests it had 
adapted to the SAα2,6 receptor specificity of human HAs (78). The 1997 H5N1 viruses 
isolated from patients in Hong Kong are characterized by a deletion in the NA stalk. 
Moreover, most recent H5N1 viruses isolated from terrestrial poultry possess short NA stalks 
and the NA stalks resulted in increased virulence in poultry (79).   
 
1.3.2 Viral ribonucleoprotein complex (RNP) 
More and more studies have highlighted the importance of mutations in the proteins of the 
viral replication machinery for pathogenicity and host transmission. Classical co-infection 
experiments in 1979 indicated a mixing of the components of the RNA polymerase complex 
can lead to the loss of the pathogenicity even in the presence of highly pathogenic HA and NA 
(80). Reassortants between lethal A/Vietanam/1203/04 (VN04) and nonlethal 
A/chicken/Vietnam/C58/04 (CH58) showed that exchanging hemagglutinin and 
neuraminidase genes did not alter the pathogenecity in ferret while substituting CH58 
polymerase genes can completely attenuated VN 04 virulence in ferret and reduced viral 
polymerase activity (81). A reassortant human H1N1 virus (A/Kawasaki/173/2001) carrying 
the viral RNA polymerase complex (PA, PB1, and PB2) and NP of the pandemic 1918 virus 
showed increased invasion virulence in upper and lower respiratory tracts of ferrets that was 
similar to the wild type 1918 virus. This strongly implicated that the viral RNA polymerase 
complex as a major determinant of the pathogenicity of the 1918 pandemic virus (82).  Recent 
large-scale sequence analyses revealed “signature” aa at specific positions in viral proteins 
that distinguish human influenza viruses from avian viruses. By reverse genetics, mutant 
viruses possessing signature aa in the PB2, PA, and NP of human influenza isolates ('human-
like aa') in the genetic background of an avian H5N1 virus were generated and exhibited 
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enhanced pathogenicity in mice, suggesting the involvement of these host lineage-specific aa 
in the pathogenicity of H5N1 avian influenza viruses in mammals(83).  
PA (T97I) mutations could adapt avirulent wild-bird H5N2 strain A/Aquatic 
bird/Korea/W81/05 (W81) to highly virulent virus in mice. It showed enhanced replication in 
mammalian cells but not in avian cell lines. Animal experiments also showed that the PA 
T97I mutation could increase replicative fitness in mice but not in chickens (84). Both the 
1957 and 1968 pandemic viruses possessed avian PB1 genes, in addition to avian HA, NA 
(85). Additionally, an experiment also indicated replication in mammalian cells was more 
efficient with PB1 proteins from avian than with that of human virus (86), which showed that 
avian PB1 might have a greater activity that could provide a replication advantage in 
mammalian systems. A mutation at position 627 (E627K) of the PB2 protein allows avian 
viruses to efficiently grow in humans and this mutation is considered as an important host 
range determinant (87, 88). This was supported by the fact that an H7N7 virus isolated from a 
patient with fatal pneumonia in the Netherlands in 2003 contained aa K at this position (89) 
and some of the H5N1 viruses isolated from patients in Vietnam are characterized by E627K 
(90), in contrast to viruses isolated from nonfatal cases and from chickens. PB2 K627 
correlates with enhanced polymerase activity, virus replication, transmission, and in certain 
cases, pathogenicity and mortality in mammals (81, 91-97). Especially, it was shown that PB2 
627K enhanced IV replication in pigs, consistent with pigs serving as an intermediary viral 
reservoir between birds and humans (98). Conversely, the presence of 627E severely 
attenuates replication efficiency and pathogenicity in mammalian systems (92, 93). Strikingly, 
approximately two-thirds of the H5N1 viruses recovered from human infections retain the 
inhibitory avian-like E627. Moreover, all of the 2009 H1N1 isolates to date possess the avian-
signature E627, but these viruses replicate and are efficiently transmitted in humans and 
animal models (99-103), which means there must be other domains or mutations to 
compensate this deficiency. A recent study revealed that the new H1N1 pandemic virus 
contains PB2 627E but its virulence can be compensated with a second site mutation, that is 
why the pandemic new H1N1 virus can evolve to enhance replication and potentially 
pathogenesis in humans (104). PB2 K627E in the A/Panama/2007/99 (H3N2) and A/Viet 
Nam/1203/04 (H5N1) backgrounds was shown to decrease transmission. Introduction of an 
701N, in conjunction with the K627E mutation, resulted in a phenotype more similar to that of 
the parental strains, suggesting that this residue can compensate for the lack of 627K in terms 
of increasing transmission in mammals (94).   
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Several studies also highlighted the importance of NP’s role in virus replication and 
pathogenecity. An avian virus NP segment against a background of a human virus resulted in 
attenuation in squirrel monkeys (105). Infection with viruses containing a 184K induced 
earlier mortality in chickens, increased virus titers and nitric oxide levels in tissues, and 
resulted in up-regulated host immune genes, such as IFN-alpha, IFN-gamma, orthomyxovirus 
resistance gene 1 (Mx1), and inducible nitric oxide synthase (105-107). Exchanging the NP 
gene in the context of two H5N1 viruses greatly increased viral replication and expanded 
tissue tropism, thus resulting in decreased mean death times (108). Adaptive mutations 
D701N in PB2 and N319K in NP enhance binding to importin alpha1 in mammalian cells 
(109). These findings demonstrate that adaptation of the viral polymerase to the nuclear 
import machinery plays an important role in interspecies transmission of influenza virus 
(109). 
 
1.3.3 The role of multifunctional NS1 protein in pathogencity 
1.3.3.1 NS1 localization and structure  
NS1 is a 26 kDa protein of 230aa in length, depending on the virus strain. Some NS1 contain 
C-terminal truncations (110) or 7 aa C-terminal extension or/and deletions in the internal 
region. Additionally, sequence analysis shows a 7 aa C-terminal extension was gained and 
retained in human H1N1, H2N2 and H3N2 viruses from 1940s to 1980s (111). Later the 
extension was lost due to a stop codon mutation. NS1 is notionally divided into two distinct 
functional domains: an N-terminal “RNA-binding” domain (residues 1–73), which binds in 
vitro with low affinity to several RNA species in a sequence independent manner (112-114), 
and a C-terminal “effector” domain (residues 74–230), which predominantly mediates 
interactions with host-cell proteins, but also functionally stabilizes the RNA-binding domain 
(115). Full-length NS1 likely exists as a homodimer, with both the RNA-binding and effector 
domains contributing to multimerization (116). Dimerization is essential for the function of  
dsRNA binding (117) and the effecter domain. Some residues such as aa 5T, 31P, 34N, 35R, 
38R, 41K, 45G, 46R and 49T (117, 118) were reported to be involved in the interaction of 
dsRNA binding. Especially, if 38R and 41K are mutated to Ala, NS1 will lose the dsRNA 
binding activity (117).  
NS1 predominantly localizes in the nucleus, but at the later time points of infection, a 
significant proportion can also be found in the cytoplasm (111, 119-121). Within the nucleus, 
NS1 has been shown to localize to ND10 structures (122) . NS1 contains one or two 
nuclear localization sequences (NLS): NLS1 is highly conserved and involves three residues 
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(35R, 38R and 41K) which are also located in the dsRNA binding domain (111). Some NS1 
contain a NLS2 at the C-terminus which comprises the specific amino acids 219K, 220R, 
231R and 232R). Other NS1 also contain a functional nucleolar localization signal (NoLS), 
which concurrents with the NLS2 domain and involves additional basic residues (224R and 
229R) (111). The meaning of NS1 localization is unknown, however, a mutant IAV 
expressing a truncated NS1 protein unable to localize to nucleoli was not attenuated in 
replication in tissue culture (111). In contrast, extensive accumulation of IV NS1 protein in 
the nuclei causes effective viral growth in Vero cells (123). NS1 138–147 amino acid 
sequence was recognized as an nuclear export signal (NES) (124), unmasking this NES by 
mutating the adjacent aa can cause the NS1 localization change from nucleus to cytoplasm. If 
the NES domain was deleted, the total NS1 proteins totally occur in the cell nucleus. In 
transfected cells, the NES of NS1 was masked, while in infected cells, due to some host 
factors or viral factors, the NES of NS1 was unmasked and lead the dramatic change of NS1 
localization from nucleus to cytoplasm (124). 
 
1.3.3.2. NS1 can affect mRNA splicing, mRNA processing, post transcription 
modification, mRNA export and translation (as reviewed in Hale BG et al. (125))  
NS1 is a multifunctional protein involved in many steps of viral replication cycle and 
contributes to the virus virulence. This includes: 1) temporal regulation of viral RNA 
synthesis; 2) control of viral mRNA splicing; 3) enhancement of viral mRNA translation; 4) 
regulation of virus particle morphogenesis; 5) suppression of host immune/apoptotic 
responses; 6) activation of phosphoinositide 3-kinase (PI3K); and 7) involvement in strain-
dependent pathogenesis. All of these NS1 functions rely on its ability to participate in a 
multitude of protein–protein and protein–RNA interactions (125).   
NS1 was reported to regulate the splicing of viral mRNA (126-129), NS1 protein alters the 
splicing and transport of RNA polymerase II-driven transcripts (126). Inhibition of mRNA 
splicing requires the N-terminal region of NS1, but is independent of RNA-binding. However 
the inhibition of nuclear export of its own mRNA needs NS1 RNA-binding activity (126, 130, 
131). It was suggested that the regulation of viral mRNA splicing by NS1 involves a cellular 
protein (70kDa NS1-binding protein), termed NS1-BP. NS1-BP was initially identified as an 
interaction partner for NS1 in yeast two-hybrid screens (132). Given that NS1-BP 
predominantly co-localizes with the spliceosome assembly factor SC35, it was suggested that 
this protein was normally involved in cellular mRNA splicing. During influenza A virus 
infection, the cytoplasmic fraction of NS1-BP is redistributed to the nucleus, and apparently 
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co-localizes with NS1 (132). Immunofluorescence experiments have also demonstrated that 
NS1 expression caused redistribution of cellular splicing factors in the nuclei of infected cells 
(133). These reports, together with findings that NS1 can bind and disrupt complexes between 
specific small nuclear RNAs (snRNAs) (essential components of spliceosomes), highlighted 
the possible biological interaction between NS1 and the cellular mRNA splicing machinery 
(134-136).  
 
 
 
Fig.1.5: Schematic interactions of the NS1 protein, together with its known interactors. The final 20 aa C-
terminal may be natively unstructured. NS1 contains two nuclear localization sequences (NLS1 and NLS2), and 
a nuclear export sequence (NES). A nucleolar localization sequence (NoLS) has been reported for some strains, 
and is concomitant with NLS2. Residues involved in RNA-binding (38R and 41K) are implicated in the 
inhibition of OAS/RNase L, Jun N-terminal kinase, and RIG-I. Additionally, NS1 contains binding sites for: 
poly(A)-binding protein I (PABPI), p85β, importin- , nucleolin, NS1-BP, eIF4GI, hStaufen, NS1-I, PKR, 
PACT, CPSF30, poly(A)-binding protein II (PABPII), Crk/CrkL, PDZ domain-containing proteins, the viral 
polymerase, and components of the cellular mRNA nuclear export machinery (E1B-AP5, p15, NXF1, and Rae1). 
(Adapted from Hale BG (125)) 
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NS1 was reported to enhance the translation of viral mRNA and the N-terminal 113 residues 
of NS1 were required for direct stimulation of viral mRNA translations. De la Luna et al. 
suggested that NS1 selectively enhanced viral mRNA and did not affect the translation of 
non-viral mRNAs (137). Salvatore et al. showed that NS1 has a general effect on the viral and 
cellular mRNA (138). Additionally, Enami et al. demonstrated that NS1 does not affect viral 
mRNA transcription (139). The mechanism behind NS1 mediated enhanced translation is not 
clear, it was suggested to be mediated by NS1 binding to 5'UTR of viral mRNAs (137, 140), 
however, it was also suggested to be vRNA segment-specific (139) because the enhanced 
translation in a viral 5'UTR-dependent manner was not seen. Alternatively, some host cellular 
protein maybe also involved in addition to NS1 binding to 5'UTR of viral mRNAs. Viral 
mRNAs were shown to be efficiently translated even in the presence of low levels of the 
cellular eIF4F cap-binding complex (141) and the residues 81–113 of NS1 can interact with 
eIF4GI, the large subunit of eIF4F (142), implying that NS1 could bind or recruit eIF4GI, and 
thus eIF4F, to the 5'UTR of viral mRNAs, thereby preferentially increasing viral translation. 
Furthermore, as shown in Fig 1.5, 1-81 aa of NS1 could interact with PABPI, a known 
interactor of eIF4GI, independently of RNA (143) and mapping studies suggested that a 
heterotrimeric NS1–PABPI–eIF4GI complex might be possible (142, 143). In addition, NS1 
could interact with and cause the redistribution of hStaufen, a dsRNA- and tubulin-binding 
protein related to dsRNA-dependent Ser/Thr protein kinase R (PKR) (144). As hStaufen 
normally contributes towards microtubular transport of cellular mRNAs to sites of enhanced 
translation, such as polysomes, the interaction with NS1 may promote efficient viral mRNA 
translation. In support of this, a proportion of both NS1 and hStaufen have previously been 
found to co-fractionate with cytoplasmic polysomes in IAV-infected cells (144). Thus, to 
increase viral protein synthesis, NS1 appeared to interact with viral 5'UTRs, hStaufen, eIF4GI 
and PABPI to recruit viral mRNAs (at the expense of cellular mRNAs) to multi-protein 
translation-initiation complexes It is still not clear if the observed binding of NS1 to poly(A) 
sequences(145) has any role in viral mRNA translation. 
 
1.3.3.3. NS1 can affect host innate and adaptive immune response. 
Pathogenesis of viral infections depends partly on the ability of a virus to evade or suppress 
the host immune response. Recombinant viruses containing NS1 deletion (delNS1) or NS1 
with truncations demonstrated the NS1 protein plays a central role in countering the host 
immune response. DelNS1 viruses could induce large amounts of IFN and were attenuated in 
IFN-competent cells (146). Additionally, delNS1 viruses replicate more efficiently in IFN-
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deficient tissues such as Vero cells than the wild type virus (147, 148). NS1 impairs innate 
and adaptive immunity by inhibiting host signal transduction and gene expression: 
 As such, NS1 can directly block the function of 2'-5'-oligoadenylate synthetase (OAS) (149) 
and PKR (150, 151) by binding to dsRNA, which are important regulators of translation that 
can induce IFN production and the host apoptotic response. OAS is activated by dsRNA, a 
putative by-product of viral replication, and polymerizes ATP into 2'-5' oligoadenylate chains. 
These chains cause dimerization and activation of the RNase L which inhibits virus replication 
by degradation of viral  RNA (152). Data indicated that a predominant function of the NS1 
RNA-binding domain is to out-compete OAS for interaction with dsRNA, thereby inhibiting 
this host antiviral strategy (149); dsRNA also binds and activates PKR, thereby releasing PKR 
auto-inhibition. A major substrate for activated PKR is the eukaryotic translation initiation 
factor 2  (eIF2 ). The phosphorylation of eIF2  leads to a reduction in both cellular and viral 
protein synthesis (153). In vitro experiments initially indicated that NS1 may also compete 
with PKR for binding dsRNA(151). Furthermore, NS1 has been shown to interact with PKR 
in a dsRNA-independent manner, which required NS1 residues 123–127 (154, 155). However, 
dsRNA has yet to be detected in influenza A virus-infected cells (156).  
Furthermore, NS1 can inhibit retinoic acid-inducible gene I (RIG-I)-mediated induction of 
IFN by binding to RIG-1, and preventing it from binding to single-stranded RNA (ssRNA) 
bearing 5'-phosphates (157, 158). Co-precipitation of RIG-I with NS1 from A/Puerto 
Rico/8/34 (PR8) is largely dependent upon 38R and 41K in PR8/NS1 (158), suggesting that 
these two residues are involved in a potential protein–protein interaction, or that RNA acts as 
an intermediary component; also, NS1 was shown to interact with the ubiquitin ligase 
TRIM25 and then inhibits specifically TRIM25-mediated RIG-I CARD ubiquitination, 
thereby suppressing RIG-I signal transduction (159). 
 Another way of NS1 to affect innate immunity is via the activation of transcription factors 
such as ATF-2/c-Jun, NF-κB, and IRF-3/5/7, all of which stimulate IFN production (160-163). 
Such pre-transcriptional inhibition requires two residues in the NS1 that strongly contribute to 
RNA-binding: 38R and 41K (162). 
NS1 forms an inhibitory complex with NXF1/TAP, p15/NXT, Rae1/mrnp41, and E1B-AP5, 
which are important factors in the mRNA export machinery, thereby NS1 decreases cellular 
mRNA transport in order to render cells highly permissive to influenza virus replication (164). 
NS1 prevent the nuclear post-transcriptional processing of RNA polymerase II transcripts by 
binding to the cellular proteins CPSF30 (165) and PAB II (166) and inhibits the 3'-end 
processing of cellular pre-mRNAs to limit IFN-β production. The C-terminal effector domain 
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of Ud/NS1 binds directly to two zinc-finger regions in the 30 kDa subunit of cleavage and 
polyadenylation specificity factor (CPSF30) and requires  103P, 106M, 144L and residues 
184–188 of NS1 from A/Udon/72 (Ud, H3N2) (165, 167). Binding to PABPII requires 
residues 223–237 of Ud/NS1 (127).  
NS1 might also affect host adaptive immune response. In a mouse model, a H5N1 NS1 
protein was shown to reduce systemic and pulmonary pro-inflammatory cytokines and 
prevented TNF- -mediated bone marrow lymphocyte depletion (168). Furthermore, in 
human-derived primary DCs, PR8/NS1 was shown to limit induction of several genes 
involved in DC maturation and migration (169). Consequently, infected DCs were unable to 
mature, and failed to stimulate the secretion of IFN-  from helper T-cells. The limitation of 
gene-expression in DCs is specific only for certain genes, and mechanistically appears 
unrelated to the suppression of IFN-β production by PR8/NS1 (169). Recent studies 
demonstrated that protection against IV infection requires reactivation of memory T-cells by 
antigens presented on bone marrow-derived DCs (170), so the prevention of DC maturation by 
NS1 may limit virus-clearance by the host.  
 
1.3.3.4. NS1 can modulate the host pro-apoptotic and anti-apoptotic response. 
NS1 is reported to have both pro- and anti-apoptotic functions. It is suggested that NS1 
contributes temporally to both ‘early’ suppression of apoptosis and ‘late’ induction of cell 
death. Certain viral proteins, such as NA and PB1-F2, have pro-apoptotic functions (171). 
Thus, the overall temporal regulation of both pro- and anti-apoptotic mechanisms may be 
critical for the virus. Limiting apoptosis early during infection could promote events such as 
genome replication, while enhancing apoptosis later may lead to increased release of progeny 
virions. Apoptosis after viral replication may also increase the phagocytic clearance of 
infected cells, which might otherwise stimulate cell-mediated cytotoxic responses. During 
virus infection, NS1 clearly displayed anti-apoptotic function which is linked to its ability to 
limit the production and downstream effects of IFN (172). In IFN-competent MDCK cells, 
PR8 delNS1 virus induced higher levels of apoptosis than wt PR8 (172). However, in Vero 
cells, which lack IFN- /β genes, both viruses induced similar levels of apoptosis, but at a 
much slower rate than that observed in MDCK cells (172). It is not known if Vero cells are 
defective in pathways and genes other than IFN- /β, therefore one can only speculate that 
IFN- /β-antagonism by NS1 is the most important factor in limiting apoptosis. As 
catalytically active PKR is reported to play a role in apoptosis during IV infection (173), the 
direct binding and inhibition of PKR by NS1 could also lead to cell-death suppression. The 
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same may be true for NS1-mediated inhibition of pro-apoptotic OAS/RNase L (149), or the 
JNK/AP-1 stress pathway (160). The activation of the host-cell PI3K pathway has recently 
been described as an additional direct method by which NS1 may limit induction of apoptosis 
(174-176). Two polyproline motifs (amino acids 164 to 167 [PXXP]), SH3 binding motif 1 
and (amino acids 213 to 216 [PPXXP]), SH3 binding motif 2 were identified in NS1. SH3 
binding motif 1 was found to contribute to the interactions between NS1 and the p85beta 
subunit of PI3K, which activates PI3K/Akt signal pathway leading to phosphorylation of 
caspase-9 to inhibit virus induced apoptosis. Mutation in motif 1 will lead to more severe 
apoptosis than wt virus (175). 
 
1.3.4 Host antiviral response: immune response and apoptosis 
1.3.4.1 Immune response 
Host immune responses to IV involve innate immune responses, humoral and cell-mediated 
adaptive immune response. Type I interferons, such as IFN-  or IFN-β, are soluble cytokines 
that are synthesized and secreted by cells in response to virus infection, IFN acts in both an 
autocrine and paracrine manner to upregulate the expression of >300 IFN-stimulated antiviral 
genes (177).  Furthermore, intracellular expression of viral proteins, such as HA, NP and M1 
and accumulation of viral RNA species, indirectly via PKR, Toll-like receptors, such as TLR-
3 -7/8, and RNA helicase proteins, such as RIG-I and mda-5 (178-183), can activate IKK 
kinase, upstream of NF-B. Activated IKK phosphorylates IkBa leading to its ubiquitination 
and degradation. NF-B heterodimer (composed p50 and p65 subunits) are therefore released 
and can translocate into the nucleus and transactivate responsive genes including IFN genes 
(21, 184). Even if progeny virus replicates in one host cell, the host innate immune responses 
may interfere with the infection of other cells (185). Interferons may induce uninfected cells 
to enter an antiviral state that inhibits viral replication and limits virus replication and spread. 
Furthermore, studies on RIG-1 and mda-5 in IV infections showed a significant increase in 
IFN promoter activity (186). In a study using human alveolar epithelial A549 cells, type I 
IFNs were shown to be important for the activation of antiviral response genes, such as the 
Mx1 (187), PKR and 2'-5' OAS. 
Whereas the innate immune response is mainly responsible for controlling virus replication in 
the early stages of infection, adaptive immune responses are generally essential to limit the 
progression of the disease and to eliminate the virus completely (188-191). Adoptive transfer 
experiments have shown that CD8+ T memory cells can cross-protect against different AIV 
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subtypes (192). Furthermore, memory T cells induced in response to seasonal human 
influenza can cross-protect even against avian influenza H5N1 (193, 194).  
 
1.3.4.2 Apoptosis 
Influenza A and B viruses induce apoptosis in both permissive and non-permissive cells 
(195). However, the role of apoptosis induced by IV is controversial. Apoptosis was said to 
reduce viral load and pathology. Whereas the activation of caspase 3, a critical enzyme 
involved in apoptosis, has been found to enhance IV replication (196). Apoptosis was reported 
to involve PKR, IFN type I secretion and the Fas antigen-encoding gene (197). The type I IFN 
response could make cells sensitive to apoptosis signaling through FADD/caspase-8 
activation (198). 
Many intrinsic and extrinsic apoptotic induction pathways have been identified to be activated 
by viral factors in virus-induced apoptosis. The dsRNA, NS1, NA and PB1-F2 can induce 
apoptosis. PB1-F2 localizes and interacts with the mitochondrial-dependent apoptotic 
pathway. The PB1-F2 protein induces apoptosis in various cell types, including human 
monocytic cells, leading to the hypothesis that this protein functions to kill host immune cells 
responding to IV infection (28). The dsRNA could activate Fas-Fas ligand intrinsic apoptotic 
signal pathway via PKR. PKR is capable of controlling several important cell-signaling 
pathways and therefore may have multiple effects; a predominant one is increased interferon 
production and activity. NA has been shown to act via an extrinsic mechanism involving 
proapoptotic host-defense molecules by activation of TGF-beta. As shown before, NS1 could 
be proapoptotic and antiapoptotic. In addition, NS1 was shown to interfere with IFN induction, 
and related cell-signaling pathways. IV infected cells undergoing apoptosis are readily 
engulfed by macrophages (199). Infection of macrophages but not dendritic cells can trigger 
apoptosis (200). It has also been reported that specific types of differentiated airway cells may 
undergo necrotic cell death, promoting inflammatory damage in the airway (201). Apoptosis 
was observed in alveolar epithelial cells, which is the major target cell type for the viral 
replication. Apoptosis may play a major role in the pathogenesis of influenza (H5N1) virus in 
humans by destroying alveolar epithelial cells. This pathogenesis causes pneumonia and 
destroys leukocytes, leading to leukopenia, which is a prominent clinical feature of influenza 
(H5N1) virus in humans. Whether observed apoptotic cells were a direct result of the viral 
replication or a consequence of an overactivation of the immune system requires further 
studies (202). 
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1.4. Aim of this project 
1.4.1. To investigate the effect of different NS segments from H5 and H7-type HAPIV on 
the replication of a strictly avian H7-type HPAIV 
Since 1997, the outbreak of an H5N1 HPAIV has resulted in major losses to the poultry 
industry and caused about 467 human infections with approximately 60% mortality (203, 
204).  The virus firstly emerged in Asia but has now spread to many countries throughout 
Europe and Africa and has the potential to cause a worldwide pandemic. H7-type HPAIV 
strains have circulated in Europe for many years and have resulted in some infections in 
humans, albeit with low mortality rates (205). With the rapid spread of H5N1 viruses into 
Europe it is increasingly likely that H5-type viruses may reassort with H7-type HPAIV. As it 
has previously been reported that H5N1 HPAIV NS segments selected after 1998 enhance 
virus replication in mammalian cells (206), while we have previously shown that a NS 
segments of A/Goose/Guangdong/1/96 (GD, H5N1) isolated in 1996 could increase the 
replication and pathogenicity of a H7-type HPAVI FPV (207). Therefore I was interested to 
investigate other NS segments from A/Vietnam/1203/2004 (VN, H5N1) isolated in 2004 and 
from A/Mallard/NL/12/2000 (Ma, H7N3) in 2000 and tried to determine how different H7- 
and H5-type NS segments affect H7-type HPAIV. 
Phylogenetic analysis of the of influenza A viruses NS segments shows that they can be 
classified into two groups: allele A and allele B (208). NS segments of human, swine, most 
equine and some avian IV belong to allele A, while NS segments of one equine and avian IV 
are grouped into allele B (110, 209, 210). The only example of an allele B NS segment from a 
mammalian IV, A/Equine/Jilin/89, originated in China and caused severe disease and high 
mortality in horses. The virus appeared to have crossed to horses from an avian source since 
all eight segments appeared to be avian-like (210). Although four allele B NS segments were 
reassorted into FPV background and rescued the viruses showed attenuated growth in squirrel 
monkeys (211). It was previously shown that a reassortant H7N1 HPAIV bearing an allele B 
NS segment of A/Goose/Guangdong/96 (GD, H5N1) was more virulent than the wild-type 
H7N1, and can productively infect mice (212). Here, I extended our study to another allele B 
NS segment which is similar to the GD NS and tried to see whether this allele B NS segment 
can also increase the replication and virulence of FPV. Furthermore, I also included another 
allele A-type NS segment in my investigation on the effect of NS reassortantant on H7-type 
HPAIV replication. 
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1.4.2 Defining molecular mechanisms that explain how NS segments affect the 
propagation of FPV  
1.4.2.1 Effects on the viral replication cycle including genome replication/transcription 
and export of viral genome  
Many studies have highlighted the importance of the interaction between RNP complex and 
NS1 in virulence and pathogenecity (213-216). NS1 protein can be immunoprecipated with 
RNP complex in vivo (213), and truncated NS1 affect the viral vRNA production in infected 
MDCK cells, while cRNA and mRNA production were not affected at the restrictive 
temperature, which indicated that NS1 is involved in replication but not in transcription (214). 
Furthermore, NS1 protein regulates the time course of viral RNA synthesis  during infection: 
a recombinant Ud virus that expresses an NS1 protein in which only two aa (123 and 124) are 
changed to Ala deregulates the normal time course of viral RNA synthesis that occurs in cells 
infected by wt Ud virus (155). Influenza A virus polymerase can be an integral component of 
CPSF30-NS1A protein complex in infected cells(215). The NS1 of influenza B virus was said 
to form a complex with RNP complex intermediated by PKR (217). In addition, NS2/NEP 
was shown to regulate the replication and transcription activity independent of RNP export 
mechanism (216). In general, the viral replication (vRNA production) is dependent on the 
viral RdRp while transcription (viral mRNA production) is critically affected by many cellular 
transcription factors such as cellular DNA-dependent RNA polymerase II (pol II), cellular 
splicing factor and cellular mRNA transport factors (51). NS1 protein was shown to interact 
with pol II (218), splicing factor [122] and cellular mRNA transport complex (164). NS2 was 
reported to interact with viral RNP export and regulate viral transcription and replication. 
However, how the components of NS segment act on the viral RNP complex and how it 
works is still unclear. 
Based on above questions, this study investigates how different NS segments affect the 
transcription/replication and the export of  the viral genome of an H7-type AIV.. 
 
1.4.2.2 Modulation of antiviral host response: stimulation of the IFN response and 
induction of apoptosis 
In this study, a series of recombinant A /FPV/Rostock/34 viruses with NS segments from 
A/FPV/Rostock/34  (FPV, H7N1), A/Goose/Guangdong/1/96 (GD, H5N1), 
A/Vietnam/1203/2004 (VN, H5N1)18, and A/Mallard/NL/12/2000 (Ma, H7N3) were 
generated by reverse genetics. As mentioned before (section 1.3.3.3 and section 1.3.4.1), NS1 
protein is one of major factors for pathogenicity by affecting the host antiviral immune 
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response and apoptosis. It can impair host innate and adaptive immunity in a number of ways 
(as mentioned in section 1.3.3.3 and section 1.3.4.1), In order to determine the effect of NS 
segment on host antiviral response and how they affect the virus propagation, the host 
antiviral response including interferon response and apoptosis were examined. 
 2. Materials and Methods 
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2. Materials and Methods  
2.1. Materials  
2.1.1. Instruments  
Abbocath-T (26Gx19mm) Hospira 
Bacterial incubator and shaker (CH 4103) Infors AG 
Bio Imaging Analyzer (BAS 2000) Fuji Film 
Cell culture incubator  Heraeus; Nuaire 
Cell culture microscope Hund 
Confocal laser scanning microscopy (TCS SP5) Leica 
Culture Hood (HB2448) Heraeus 
Developing machine Optimax, Protec 
Disposable Razor Med Comfort AMPri GmbH 
DNA-Spectrophotometer GeneQuant II Pharmacia Biotech 
Electrophoresis apparatus system Institute for Medical Virology 
Electrophoresis power supply (EPS500/400) Pharmacia 
ELISA reader (Type LP 400)  Diagnostic Pasteur 
FACS calibur Becton Dickinson, USA 
Fine scale (Mettler PM460) Mettler Waagen GmbH 
Gene Pulser Biorad 
GeneQuant II (RNA/DNA calculator) Pharmacia Biotech 
Heat block Jumotron 
BioMax TranScreen HE Intensifying Screen with 
BioMax Cassette 
Kodak 
Magnetic stirrer IKA Labortechnik 
Megafuge 1.0 R Heraeus 
Microwave oven Quelle 
Mini centrifuge Biofuge 13, Heraeus 
PCR machine (GeneAmp, PCR system 2400) Perkin Elmer 
pH meter (Type 632) Metrohm 
Photo system for gel (P93D)  Mitsubishi 
Shaker (Type 3013) MSGV GmbH 
Scale (P1200) Mettler 
Scanner Canonscan 9900F Canon 
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SDS-PAGE gel system Institute for Medical Virology 
Sonicator (Type HD70) Bondelin Sonoplus 
Spectrophotometer (DU-70) Beckman 
Speed Vac (SPD111V) Savant 
Sterile needles  BD Microlance 3 BD  
Syringe (microliter, serial 700) Hamilton 
Syringe 20ml single use Braun, Melsungen AG 
Thermomixer Eppendorf 
UV light source Vilber Lourmat 
Vortex (Vibrofix VF1) IKA Labortechnik 
Water bath (SW-20C) Julabo 
Western-Blot chamber  Institute for Medical Virology 
  
 
2.1.2. Reagents and general materials 
1 kb DNA ladder mix PEQLAB 
10x restriction enzyme buffer 1, 2, 3 and 4 NEB 
10x AccuPrime Pfx DNA polymerase buffer Invitrogen 
Acrylamide     Bio-Rad 
Acrylamide/Bisacrylamide 19:1 premixed solution Appligene 
AccuPrime dNTPs (3 mM) Invitrogen 
Accutase PAA 
Acetic acid Roth 
Agar high-gel strength Serva 
Agarose ultra pure Roth 
Ammonium persulfate (APS)   Serva 
Ampicillin ICN 
Aprotinin  Roth 
Avicel-Powder (Avicel microcrystalline cellulose NF, 
B.P.) 
IMCD Germany 
β-mercaptoethanol (MetOH)  Roth 
Benzamidin  Sigma 
Blotting papers (GB004) Scheicher & Schuell 
Boric acid Roth 
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Bradford reagent Biorad 
Bromophenol blue Merck 
BSA (Solution, 35%) MP Biomedicals 
BSA (Powder) Roth 
Casein Bacto-Casitone Difco Laboratories 
Chloroform Roth 
Coomassie brilliant blue R 250 Merck 
Cryotubes Nunc 
DAB Peroxidase substrate  
(3,3’-Diaminobenzidine) 
Sigma 
DAPI (stock 1mg/ml) Roth 
DEAE Dextran (MW: 500,000) Pharmacia Biotech 
1,4-Diazabicyclo 2,2,2octane (DABCO) Merck 
Dimethylsulfoxid (DMSO) Sigma 
Di-Sodium hydrogen phosphate anhydrous (Na2HPO4) Merck 
1,4-Dithiothreit (C4H10O2S2) (DTT) Roth 
DNA loading buffer (6x) PeqLab 
Electro cuvette Biorad 
Eppendorf tube  Eppendorf 
Ethanol (absolute) Roth 
Ethidium bromide Roche 
Ethylenediamine tetraacetic acid (EDTA) Fluka 
Extract of yeast powder Merck 
Falcon centrifuge tube Falcon 
Formamid  Fluke 
Glycerol Sigma 
Glycine Roth 
Hydrochloride (HCl) Roth 
Isoamyl alcohol Roth 
Isopropanol Roth 
Kodak® BioMax™ MS film (20cm×25 cm) Sigma 
Leupeptin Sigma 
Lipofectamine  and Plus Reagent Invitrogen 
Lipofectamine 2000 Invitrogen 
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Magnesium chloride (MgCl2) Merck 
Methylcellulose (methocel MC) Sigma 
Microtiter plate (96 wells) Greiner 
Mowiol 40 - 88 Aldrich 
Methanol Roth 
N-2-hydroxyethylpiperazine (HEPES)  Sigma 
Oxoid Agar Oxoid 
Paraformaldehyde (PFA) Merck 
Pefablock Roth 
Peptone from meat trypsin-digested  Merck 
Potassium chloride (KCl) Roth 
Polystyrene round-bottom tube (5ml) Becton Dickinson 
Precision Plus Protein Standards (All Blue) BioRad 
Potassium dihydrogen phosphate (KH2PO4) Roth 
Propidium Iodide Sigma 
PVDF-Membrane Immobilon-P transfer membrane  Millipore 
Quartz crystal cuvette Hellma GmbH 
Rainbow marker  Amersham 
Re-Blot Plus – strong antibody stripping solution Chemicon 
Roti-Free, ready-to-use Stripping Buffer  Roth 
Röntgenfilme BioMax MR Kodak 
Roti-phenol Roth 
RPMI 1640 Invitrogen 
Roti-phenol/ chloroform Roth 
SOC medium Invitrogen 
Scientific Imaging film BioMax MR  Kodak 
Sodium chloride (NaCl) Roth 
Sodium dodecyl sulfate (SDS) Merck 
Sodium-β-glycerophosphate Sigma 
Sodium hydroxide (NaOH) Merck 
Sodium hydrogen carbonate (NaHCO3) Fluka 
Sodium orthovanadate Sigma 
Sodium pyrophosphate Sigma 
TEMED (N,N,N',N'-Tetramethyl-ethylene diamine) Serva 
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TLC plates (20 x 20 cm Silica gel 60) Merck 
Trypsin-EDTA (10×) PAA Laboratories GmbH 
Tris HCl Roth 
Triton X-100 (t-Octylphenoxypolyethoxyethanol) Sigma 
Trizol Reagent Invitrogen 
Tween 20 Roth 
Urea Sigma 
Whatman 3MM Papier Schleicher & Schüll 
Xylene cyanole Sigma 
  
2.1.3. Monoclonal and polyclonal antibodies 
Antibody Company Dilution 
Anti-P-ERK (E-4) mouse monoclonal IgG Santa Cruz Biotechnology 1:250 
Anti-ERK2 (C-14) mouse monoclonal IgG Santa Cruz Biotechnology 1:500 
HRP conjugated goat anti-mouse IgG Santa Cruz Biotechnology 1:1000 
Anti-flu A NP (FPV) mouse (clone 1331) Biozol–Biodesign Internat. 1:6000 
Anti-influenza A FPV/Rostock/34 rabbit 
polyclonal serum 
Marburg 1:1000 
Texas Red conjugated rabbit anti-mouse Dianova 1:200 
   
  
2.1.4. Materials for cell culture  
Chicken Serum Sigma Aldrich 
Dulbecco's Modified Eagle's medium (DMEM) Invitrogen/Gibco 
Fetal calf serum (FCS) PAN 
L-Glutamine 100× (200mM, 29.2 mg/ml in 0.85% 
NaCl) 
Invitrogen 
Penicillin/Streptomycin, 100× liquid (Contains 10,000 
units of penicillin (base) and 10,000 µg of 
streptomycin (base)/ml utilizing penicillin G (sodium 
salt) and Streptomycin sulfate in 0.85% saline.) 
PAA  
Trypsin-EDTA (10x) PAA 
Tissue culture dish  Becton Dickinson 
Tissue culture flask NUNC 
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Tryptose Phosphate Broth Sigma Aldrich 
Bovine Albumin 30% PAA 
 
2.1.5. Enzymes 
AccuPrime Pfx DNA Polymerase Invitrogen 
GoTaq flexi DNA polymerase Promega 
PlatinumR Pfx DNA polymerase Invitrogen 
SuperScript TM III reverse transcriptase Invitrogen 
T4 polynuleotide kinase (10,000 units/ml) NEB 
Restriction endonucleases NEB 
RQ1 RNase free DNase  Promega 
  
2.1.6. Kits 
AEC staining kit Sigma 
Anti-human IFN beta ELISA kit BioSource/Invitrogen 
ECL (enhanced chemiluminescence) solution kit Amersham/GE 
High pure PCR product purification kit Roche 
In situ cell death detection kit, fluorescein Roche 
NucleoPond Xtra Maxi kit for DNA plasmids prep Macherey-Nagel 
pcDNATM 3.1 directional TOPO expression Kit Invitrogen 
QIAprep Spin Miniprep Kit (250) Qiagen 
QIAamp Viral RNA Mini Kit (250) Qiagen 
Qiagen plasmid maxi kit Qiagen 
Rapid DNA ligation kit Roche 
TOPO XL PCR cloning kit Invitrogen 
Lifpofectamine 2000 Invitrogen 
Lifpofectamine TM Invitrogen 
  
 
2.1.7. E. coli strain, recombinant viruses and cell lines  
E. coli strain  
XL1-Blue Stratagene 
TOP 10 Invitrogen 
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Recombinant influenza viruses  
A/FPV/Rostock/34 (H7N1) (FPV wt) Rescued at the Institute of 
Virology, Giessen 
FPV NS GD Rescued at the Institute of 
Virology, Giessen 
FPV NS VN Rescued at the Institute of 
Virology, Giessen 
FPV NS Ma Rescued at the Institute of 
Virology, Giessen 
  
Cell line  
A549 (Human Alveoar Epithelial cells) Cell-collection the Institute of 
Virology Giessen 
MDCK-II  (Madin-Darby canine kidney cells) Cell-collection the Institute of 
Virology Giessen 
Vero (African Green Monkey cells) Cell-collection the Institute of 
Virology Giessen 
293T (Human embryonic kidney cells) Cell-collection the Institute of 
Virology Giessen 
QT6 (quail fibroblast cells) Kind gift from the Institute for 
Virology, Marburg 
LMH (chicken hepatocellular carcinoma cells) Kind gift from the Institute for 
Virology, Marburg 
Mice primary aveleoar epithelial cells Isolated the Institute of Virology 
Giessen 
  
2.1.8. Plasmids  
pPolI-FPV -PB1 (A/FPV/Rostock/34 (H7N1)) Kind gift from the Institute for 
Virology, Marburg  
pPolI-FPV -PB2 (A/FPV/Rostock/34 (H7N1)) Kind gift from the Institute for 
Virology, Marburg 
pPolI-FPV -PA (A/FPV/Rostock/34 (H7N1)) Kind gift from the Institute for 
Virology, Marburg 
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pPolI-NP (A/FPV/Rostock/34 (H7N1)) Kind gift from the Institute for 
Virology, Marburg 
pPolI-FPV -HA (A/FPV/Rostock/34 (H7N1)) Kind gift from the Institute for 
Virology, Marburg 
pPolI-FPV -NA (A/FPV/Rostock/34 (H7N1)) Kind gift from the Institute for 
Virology, Marburg 
pPolI-FPV -M (A/FPV/Rostock/34 (H7N1)) Kind gift from the Institute for 
Virology, Marburg 
pPolI-FPV-NS (A/FPV/Rostock/34 (H7N1)) Kind gift from the Institute for 
Virology, Marburg 
pCI-GD-NS (A/Goose/Guangdong/1/96 (H5N1)) Kind gift from the Institute for 
Virology, Marburg 
pPolI-VN-NS (A/Vietnam/1203/2004 ( H5N1)) Kind gift from RKI, Berlin 
pPolI-Ma-NS (A/Mallard/NL/12/2000 (H7N3)) Kind gift from the Institute for 
Virology, Helsinki 
pHMG-PA (A/Puerto Rico/8/34(H1N1)) Kind gift from the Institute for 
Virology, Zurich 
pHMG-PB1 (A/Puerto Rico/8/34(H1N1)) Kind gift from the Institute for 
Virology, Zurich 
pHMG-PB2 (A/Puerto Rico/8/34(H1N1)) Kind gift from the Institute for 
Virology, Zurich 
pHMG-NP (A/Puerto Rico/8/34(H1N1)) Kind gift from the Institute for 
Virology, Zurich 
pcDNA3.0-PR8-NS1 (A/Puerto Rico/8/34(H1N1)) Kind gift from the RKI, Berlin 
pPolI-GFP-RT (Human Pol promoter) Constructed in AG Pleschka,  
Giessen 
pPolI-CAT-RT (Human Pol promoter) Kind gift from the department of 
microbiology, Mountain Saint 
School of Medicine,  New York 
pK9-CAT(469) (Canine Pol promoter) kindly provided by MedImmune 
pCI-NP (A/Goose/Guangdong/1/96 (H5N1)) Constructed at the Institute of 
Virology, Giessen 
pCI-PB1 (A/Goose/Guangdong/1/96 (H5N1)) Constructed at the Institute of 
Virology, Giessen 
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pCI-PB2 (A/Goose/Guangdong/1/96 (H5N1)) Constructed at the Institute of 
Virology, Giessen 
pCI-PA (A/Goose/Guangdong/1/96 (H5N1)) Constructed at the Institute of 
Virology, Giessen 
pcDNA3.1-GD-NP(A/Goose/Guangdong/1/96 
(H5N1)) 
Constructed at the Institute of 
Virology, Giessen 
pcDNA3.0-GD-PB1(A/Goose/Guangdong/1/96 
(H5N1)) 
Constructed at the Institute of 
Virology, Giessen 
pcDNA3.0-GD-PB2(A/Goose/Guangdong/1/96 
(H5N1)) 
Constructed at the Institute of 
Virology, Giessen 
pcDNA3.0-GD-PA(A/Goose/Guangdong/1/96 
(H5N1)) 
Constructed at the Institute of 
Virology, Giessen 
pcDNA3.0-GD-NS1(A/Goose/Guangdong/1/96 
(H5N1)) 
Constructed at the Institute of 
Virology, Giessen 
pcDNA3.0-GD-NS2(A/Goose/Guangdong/1/96 
(H5N1)) 
Constructed at the Institute of 
Virology, Giessen 
pcDNA3.1-FPV-NP (A/FPV/Rostock/34 (H7N1)) Constructed at the Institute of 
Virology, Giessen 
pcDNA3.0-FPV-PB1(A/FPV/Rostock/34 (H7N1)) Constructed at the Institute of 
Virology, Giessen 
pcDNA3.0-FPV-PB2(A/FPV/Rostock/34 (H7N1)) Constructed at the Institute of 
Virology, Giessen 
 
pcDNA3.0-FPV-PA(A/FPV/Rostock/34 (H7N1)) 
 
Constructed at the Institute of 
Virology, Giessen 
pcDNA3.0-FPV-NS1(A/FPV/Rostock/34 (H7N1)) Constructed at the Institute of 
Virology, Giessen 
pcDNA3.0-FPV-NS2(A/FPV/Rostock/34 (H7N1)) Constructed at the Institute of 
Virology, Giessen 
pcDNA3.0-VN-NS1 (A/Vietnam/1203/2004 ( H5N1)) Constructed at the Institute of 
Virology, Giessen 
pcDNA3.0-VN-NS2 (A/Vietnam/1203/2004 ( H5N1)) Constructed at the Institute of 
Virology, Giessen 
pcDNA3.0-Ma-NS1 (A/Mallard/NL/12/2000 (H7N3)) Constructed at the Institute of 
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Virology, Giessen 
pcDNA3.0-Ma-NS2 (A/Mallard/NL/12/2000 (H7N3)) Constructed at the Institute of 
Virology, Giessen 
  
2.1.9. Media and gels 
  
Avicel Medium (100ml)  
10ml 10x MEM 
33ml ddH2O 
1ml Penicillin/Strepromycin liquid (100x) 
1ml BSA (Solution, 35%) 
50ml Avicell Stock (2.5%)  
1ml 1% DEAE-Dextran  
4ml NaHCO3 (7.5%) 
 
  
Avicel Stock (2.5%)  
5g Avicel-Powder  
200ml ddH2O  
autoclaved 
 
  
Cell culture medium for LMH cells (500ml)  
440ml RPMI 1640 
5ml Penicillin/Strepromycin liquid (100x) 
5ml L-Glutamin 
40ml FCS 
10ml chicken Serum 
 
  
Cell culture medium for QT6 cells (500ml)  
425ml HAM's-F10 media 
5ml  Penicillin/Strepromycin liquid (100x) 
5ml L-Glutamine 
50ml Fetal Calf Serum (FCS) 
5ml Chicken Serum 
10ml Tryptose Phosphate Broth 
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DEAE Dextran (1%)  
1g Dextran  
Dissolve in 100ml dH2O 
Autoclave it 
 
  
Cell fixing buffer (100ml)  
95ml PBS++ 
4ml 37% Formaldehyde (PFA) 
1ml Triton X-100 (t-Octylphenoxypolyethoxyethanol) 
 
 
 
 
DMEM/10% FCS/P/S (complete DMEM 0.5L)  
445ml DMEM 
50ml FCS (heat inactivated) 
5ml Penicillin/Strepromycin liquid (100x) 
 
  
DMEM/BA (0.5L) 
 
 
492ml DMEM 
5ml penicillin/streptomycin (100x) 
3ml Bovine Albumin (BA) (35%)  
  
Dulbecco´s Modified Eagle Medium (DMEM 10L)  
 
 
1x DMEM powder high glucose 
37 g/10 L bicarbonate 
100ml/10 L sodium pyruvate 
100ml/10 L penicillin/streptomycin, liquid (100x) 
sterile filtered 
 
  
Luri-Broth (LB) medium  
0.5% (w/v) Extract of yeast powder 
1% (w/v) Peptone from meat trypsin-digested 
1% (w/v) NaCl 
adjust pH to 7.5 with NaOH and total volume to 1 L 
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with ddH2O, autoclaved 
for plates, add 1.5% (w/v) agar high-gel strength, 
autoclaved 
  
Methyl cellulose media, 1.5% stock (100ml) for Foci 
assay 
 
50ml methyl cellulose stock (3%) 
1ml Penicillin/Strepromycin liquid (100x) 
1ml BA (30%) 
10ml MEM (10x) 
4ml NaHCO3 (7.5%) 
1ml DEAE Dextran (MW: 500,000) (1%) 
33ml ddH2O 
mix well and store at 4°C 
 
  
Methyl cellulose stock (3%)  
500ml ion free water was preheated with microwave to boiled, slowly add 15g Methyl 
cellulose power into water and until the liquid become evenly suspension solution, then the 
liquid was distributed into different bottle (100ml/bottle). Afterwards the bottles were 
placed at 4°C for overnight and then autoclaved it. The bottles were placed at 4°C for anther 
3 days, during incubation, the bottles were up and down placed for several times until no big 
clots were seen. 
 
 
Mowiol DABCO 
2.4 g Mowiol  
6 g Glycerol  
6ml ddH2O  
Mixed thoroughly over night. Next day add 12ml 0.2 M Tris-HCl (pH 8.5) and incubated at 
50°C for 30 min. Centrifuge the viscous mixture at 12000 g (Megafuge 1.0R, 6000 rpm) at 
room temperature for 15 min, and mix the supernatant with 2.5% DABCO. 
  
Plaque assay agar mixture (50ml)  
8,5ml ddH2O  
25ml 2x DMEM/BA 
 
 2. Materials and Methods 
 
 36
0,5ml 1% DEAE-Dextran (MW: 500,000) 
1ml 5% NaHCO3 
15ml 3% Oxoid agar 
  
SDS-PAGE stacking gel  
 
 
 
 
 
2,9ml ddH2O 
1,25ml Tris HCl, pH 6.8 (0.5 M) 
50  μl SDS (10%) 
750 μl polyacrylamide (PAA) (30%) 
50 μl APS (10%) 
4 μl TEMED  
  
SDS-PAGE resolving gel (10%)  
4ml ddH2O  
2,5ml Tris HCl, pH 8.8 (1.5 M)  
100 μl SDS (10%)  
3,3ml polyacrylamide (PAA) (30%)  
50 μl APS (10%)  
6 μl TEMED  
  
2x TY medium 
16 g Bacto-trypton 
10 g Bacto-yeast extract 
5 g NaCl 
adjust pH to 7.4 with NaOH and total volume to 1 L 
with ddH2O, autoclaved 
for plates, add 15 g Bacto-agar 
 
  
6%, 7M urea polyacrylamide gel 
21g urea 
5ml 10X TBE 
7.5ml 40% acrylamide 
Fill up the tube to 50ml with sterile water 
0.5ml 10% APS  
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0.05ml TEMED  
 
  
2.1.10. Buffers and solutions 
  
100x Ca2+/Mg2+ solution (100ml) 
1 g MgCl2 
1.32 g CaCl2 
ddH2O added up to 100ml 
autoclaved, then filtered with the 0.2µm filter column 
Acetate buffer (SC AEC)  
(50mM) 7.708g Ammoniumacetat  powder (M=77.08) 
(8.8mM) 534µl 30% H2O2 (Roth) 
1950ml dH2O 
 set pH to 5.0 
set total volume to 2000ml with dH2O 
 
 
AEC-staining-solution  
4ml dH2O  
2 drops Acetate-buffer  
1 drop substrate  
1 drop 3% H2O2 
 
  
DEPC (diethylpyrocarbonate) H2O  
Prepare 0.1% DEPC solution with millipore water, 
Let it sit at room temperature or more at 37ºC for 12h.  
Then autoclave it for 60 min to inactivate the DEPC.  
Check it by smelling to make sure that DEPC has 
evaporated. 
 
  
Phosphate-Buffered Saline (10x PBS) (1L)  
 
 
0.137 M NaCl 
0.27 mM KCl 
8.1 mM Na2HPO4  
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 1.47 mM KH2PO4 
adjust total volume to 1 L with ddH2O, autoclaved  
  
1x PBS++ buffer (0,5L)  
495ml 1x PBS (autoclaved) 
5ml Ca2+/Mg2+ solution (100x) 
 
  
PBS/Ca2+/Mg2+/BA/antibiotic (200ml)  
20ml 10x PBS (see above) 
174.8 ml ddH2O (sterile) 
2ml  Penicillin/Strepromycin liquid (100x) 
1.2ml BSA (35%) 
2ml  Ca2+/Mg2+ (100x) 
 
 
  
SDS-PAGE loading buffer (2x) (Laemmli Buffer)  
100 mM Tris-HCl, pH 6.8 
200 mM DTT (dithiothreitol) 
4% SDS 
20% glycerol 
0.2% bromophenol blue 
 
  
SDS-PAGE running buffer (5x) (1L)  
 
 
 
1 g SDS 
6 g Tris HCl 
28.8 g glycin 
adjust total volume to 1 L with ddH2O  
  
SDS-PAGE transfer buffer (1L)  
5.8 g Tris HCl 
2.9 g glycin 
0.17 g SDS 
200ml methanol 
adjust total volume to 1 L with ddH2O 
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Tris-Acetate-EDTA (50x TAE) 
2 M Tris HCl 
1 M acetid acid 
0.1 M EDTA 
adjust total volume to 1 L with ddH2O 
 
  
TLB buffer   
20 mM Tris HCl, pH 7.4 
137 mM NaCl 
10% (v/v) glycerol 
1% (v/v) Triton X-100 
2 mM EDTA 
50 mM sodium-β-glycerophosphate 
20 mM sodiumpyrophosphate 
(Addition of inhibitors for lysis buffer, see below) 
 
  
Lysis buffer (10ml)  
10ml TLB buffer (see TLB buffer) 
10 μl Pefablock (200 mM) 
10 μl Aprotinin (5 mg/ml) 
10 μl Leupeptin (5 mg/ml) 
100 μl Sodium orthovanadate (100 mM) 
50 μl Benzamidine (1 M) 
 
  
3x DNA loading buffer, formamide mix   
9ml Formamid p.a. (Fluka) 
1ml 100mM EDTA 
½ sparula Xylene cyanole 
½ sparula bromphenole blue 
mix, alliquot and freeze away 
 
 
Tris-Buffered Saline (10x TBS) (1L)  
 24.2 g Tris HCl 
80 g NaCl  
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 dissolve by adding 900ml ddH2O 
adjust pH to 7.6 and total volume to 1 L with ddH2O  
  
TBS/Tween (0.05%) (1x TBS-T) (1L)  
 
 
100ml 10x TBS 
900ml ddH2O 
0.5ml Tween 20   
  
Blocking buffer and antibody diluting solution  
5% (w/v) nonfat dry milk 
in 1x TBS-T (see above) 
 
  
Coomassie brilliant blue solution (100ml) 
0.25 g Coomassie brilliant blue R 250 
90ml Methanol /H2O (v/v, 1:1) 
10ml acetic acid (10% (v/v)) 
Filtered with normal filter paper. 
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2.2. Methods  
2.2.1. DNA cloning and sub cloning 
2.2.1.1. Preparation of competent cells for electroporation 
10 l glycerol stock of Escherichia coli XL1-Blue (or DH5α) strain was transferred into 10 ml 
LB medium. Cells were grown overnight at 37C on the incubator shaker with moderate 
shaking (200 rpm). 10ml overnight culture was transferred into 1 L LB medium. Cells were 
grown for additional 3-4 hours at 37C until the OD595 reached 0.5-0.8. After cooling down on 
ice for 30 min, cells were transferred into four sterile 250ml centrifugation tubes and pelleted 
by centrifugation for 10 min at 10,000 rpm (Biofuge 13, 16,000 g), 4C. Then cells were 
sequentially resuspended in 500ml of chilled 1 mM HEPES (pH 7.0), pelleted again by 
centrifugation and resuspended in 250ml of chilled 1 mM HEPES (pH 7.0), pelleted by 
centrifugation again as above. The cells were resuspended in 50ml chilled 10% glycerol in 
ddH2O, centrifuged again as above and resuspended in 2.5-3ml 10% (v/v) glycerol. 
Competent cells were aliquoted in 100 l on ice. The tubes containing the competent cells 
were placed into fluid nitrogen to be frozen, and then stocked immediately at -70C.  
 
2.2.1.2. Electroporation 
This should be prepared before performing electroporation: 
Chilled sterile electro cuvette 
1ml sterile SOC medium in an eppendorf tube 
Thaw competent cells rapidly on ice 
 
Transformation equipment setting: 
Ohm: 200 
Capacitance: 25 
Voltage: 2.5 KV 
Time: time Const 
10 µl of plasmid DNA (10 ng/µl) or 20 l of desalted ligation mixture was mixed in 100 l of 
rapidly thawed competent cells by stirring gently with the pipette tip. Transformation mixture 
was added into the chilled cuvette, then cuvette was quickly wiped and placed into the device 
of the Gene Pulser. Then two red buttons were pushed simultaneously until a signal was heard 
(the expected electroporation time is about 4 ms). Immediately 1ml of SOC medium was 
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added into the cuvette and mixed with the cells. The cells and SOC medium were removed 
from the cuvette and transferred into the eppendorf tube, then incubated in the 37C water 
bath for 30-45 min. If ligation mixture was transformed, the cells and SOC medium mixture 
was centrifuged shortly after incubation, then only 100 µl medium was kept in the eppendorf 
tube, rest of supernatants were discarded. The cell pellet was resuspended in the 100 µl liquid 
as mentioned and spread onto a pre-warmed LB plate containing 100 µg/ml ampicillin. The 
plates were incubated overnight at 37C (plasmid transformed bacteria are selected on LB 
plates with ampicillin). Afterwards one single colony was picked and inoculated in LB 
medium with ampicillin and shaken overnight at 37°C. The bacteria culture was then used for 
preparing plasmid DNA and frozen glycerol stocks by mixing 850 µl bacteria culture with 150 
µl autoclaved 100% glycerol. 
 
2.2.1.3. Preparation of plasmid DNA 
Plasmid DNA maxi preparation was preformed using QIAprep plasmid midi or maxi kit. The 
culture of bacteria containing plasmids was grown in 100ml of LB media overnight in 37°C 
incubator with shaking at 200 rpm. The bacteria were collected by centrifuging the overnight 
culture at 6,000 rpm (Beckman JA14, 7,500 g) and 4°C for 15 min. There after the bacterial 
pellet was resuspended in 10ml of buffer P1 and 10ml buffer P2 was added. The whole 
mixture was mixed gently and incubated at room temperature for 5 min. 10ml of chilled 
buffer P3 was added, mixed immediately and incubated on ice for 20 min. The mixture was 
centrifuged at 4,000 rpm (Megafuge 1.0R, 5,400 g) for 30 min at 4°C. The supernatant was 
applied to an equilibrated QIAGEN-tip 500 and allowed to enter the resin by gravity flow. 
The QIAGEN-tip was washed twice with 30ml buffer QC. DNA was eluted with 15ml buffer 
QF. The DNA is precipitated by adding 0.7 volumes (10.5ml) of isopropanol and 
centrifugation at 12,000 rpm (Beckman JA20, 21,000 g) for 30 min at 4°C. The resulting 
pellet was washed twice with 70% ethanol and air-dried at room temperature. The pellet is 
then carefully resuspended in certain volume of TE buffer depending on the size of DNA 
pellet. The concentration of plasmid DNA was photometric measured and adjusted to 1 µg/µl. 
The plasmid DNA can be stored at 4°C for a short time only or at -20°C over a longer period. 
 
2.2.1.4. Measurement of plasmid DNA concentration 
The DNA concentration is determined by using a DNA photometer (GeneQuant II) at 
wavelength of 260 nm. The absorption of 1 at 260 nm corresponds to a concentration of 50 
µg/ml double stranded DNA. First of all an appropriate DNA dilution (normally 1:100) was 
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made, transferred into a quartz crystal cuvette and placed into the photometer, which has been 
calibrated before to the solvent (either H2O or TE buffer). The desired OD should lie between 
0.2 and 0.4 to ensure correct measurement. 
 
2.2.1.5. Restriction endonuclease digestion 
Digestion of DNA with restriction endonuclease was performed by pipetting DNA sample, 
10x restriction buffer, restriction enzyme, and distilled and deionized water (ddH2O) in a 
1.5ml eppendorf tube. The reaction mixture was incubated at the recommended temperature 
(usually at 37°C). Normally 1 or 5 Units of restriction enzyme were used to digest 1 g DNA.  
 
2.2.1.6. Agarose gel electrophoresis 
The agarose (1-3%) was melted in 1X TAE buffer using a microwave oven, and cooled to 
about 55oC. Before the gel was poured into a casting platform, ethidium bromide (4 µl of 10 
mg/ml in 100ml solved agarose) was added. DNA samples were mixed with appropriate 
amount of 6x loading buffer before loaded into the wells. Normally, the gel was run with 100-
120 V and 300-400 mA. DNA was visualized by placing gel on a UV light source and picture 
was photographed directly by a photo system. 
 
2.2.1.7. Preparation of DNA fragments 
DNA bands were excised from gel and subsequently purified with a High pure PCR product 
purification kit (Roche). The preparation was performed according to the manufacturer’s 
instruction. After purification, 5 l of the purified DNA was run on agarose gel for determing 
the DNA amount for ligation.  
 
2.2.1.8. Ligation 
Ligations were done with a rapid DNA ligation kit (Roche). Each 4 µl of linearized vector 
DNA and purified DNA fragment were used. The exact operation was performed according to 
the manufacturer’s instruction. The ligation products were purified with high pure PCR 
product purification kit according to the manufacturer’s instruction, before they were used for 
electroporation. 
 
2.2.1.9. TOPO directional cloning  
2.2.1.9.1. PCR to produce Blunt-End Products 
PCR reaction mixture in 50 µl voloume:  
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Template (10 ng/µl)                  1.0 µl 
forward primer (10 pmol/µl)                 3.0 µl 
backward primer (10 pmol/µl)     3.0 µl 
10×Pfx Amplification Buffer                                                   11.25 µl 
10 mM dNTP mixture                                                                         1.0 µl 
50 mM MgSO4                                                                                   1.0 µl 
Platinum® Pfx DNA Polymerase (2.5 U/µl, Invitrogen)  1.0 µl 
ddH2O         to 50 µl 
The mixture was denatured for 2 min at 94°C. 25-35 cycles of PCR amplification was perform 
as follows:  
Denaturation   15 s   95oC 
Annealing   30 s   55oC 
Extension   2 min   68°C for 1 min per kb 
Final extension  10 min   68oC 
Cool down to 4oC, Samples can be stored at -20°C until use. 
 
2.2.1.9.2. Cloning of the PCR fragments into pcDNA™3.1 directional TOPO® 
expression vector  
The principle for the directional TOPO expression vector is shown in the Fig 2.1 (adapted 
from the Invitrogen kits description. 
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Fig 2.1:  Directional TOPO cloning: In this system, PCR products are directionally cloned by adding four bases 
to the forward primer (CACC). The overhang in the cloning vector (GTGG) invades the 5′end of the PCR 
product, anneals to the added bases, and stabilizes the PCR product in the correct orientation. Inserts can be 
cloned in the correct orientation with efficiencies equal to or greater than 90%. (modified from invitrogen 
directional ROPO cloning kit description) 
 
A 0.5:1 to 2:1 molar ratio of PCR product:TOPO vector was set up in cloning reaction as 
followed: 
Fresh purified PCR product                4.0 µl 
Diluted 6×Salt solution                                                          1.0 µl 
TOPO vector                                        1.0 µl 
The final volume of mixture is 6.0 µl and the mixture was incubated at room temperature for 5 
min (if the cloning fragments is more than 1kb, incubation time can be varied from 5min to 
30min). Afterwards electroporation was performed. Positive clones were detected after 
plasmid DNA isolation and restriction analysis. 
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2.2.3. Working with cell cultures 
2.2.2. Maintenance of cell culture 
2.2.2.1 Maintenance of mammalian and avian cell culture 
MDCK (Mardin-Darby canine kidney cells), A549 (Human Alveoar Epithelial cells), Vero 
(African Green Monkey cells) and 293T (Human embryonic kidney cells) are maintained in 
Dulbecco modified Eagles medium (DMEM) containing phenol red as a pH-indicator, 
supplemented with 10% heat inactivated fetal calf serum (FCS) and P/S. The cells are 
incubated at 37°C with 5% CO2 and 95% humidity. They are routinely cultured to a 100% 
confluence and than passaged according to the need. 
QT6 (quail fibroblast cells) were maintained in HAM's-F10 media containing 1% L-
Glutamine, supplemented with 8% heat inactivated fetal calf serum (FCS), 2% Chicken 
Serum, 2% Tryptose phosphate broth and P/S LMH (chicken hepatocellular carcinoma cells) 
were maintained in RPMI 1640 containing 1% L-Glutamine, supplemented with 8% heat 
inactivated fetal calf serum (FCS), 2% Chicken Serum and P/S. The cells are incubated at 
37°C with 5% CO2 and 95% humidity. They are routinely cultured to a 100% confluence and 
than passaged according to the need. 
 
2.2.2.2. Mice primary cell isolation and maintainance 
Mice primary alveolar epithelial cells (AECs) were isolated as previously described (Corti et 
al., Am J Respir Cell Mol Biol, 1996) but with some modifications. C57BL/6 mice were 
euthanised by an overdose of isoflurane and exsanguinated by cutting the inferior vena cava. 
Lungs were then perfused with 20ml of sterile HBSS via the right ventricle until they were 
clean of blood. A shortened 21-gauge cannula was then firmly fixed to the exposed trachea 
through a small incision performed on the trachea. 1.5ml of sterile dispase (enzyme used for 
digestion) was then applied through the needle into the lungs followed by 500 µl of sterile 1% 
low melting agarose in PBS (37oC). After 2 min of incubation, the lungs were removed into a 
15ml tube containing 2ml of dispase and allowed to incubate for a further 40 min at RT. The 
lungs were then placed in a culture dish containing DMEM/2.5% HEPES buffer/0.01% 
DNase (also enzyme used for digestion), and the tissue was carefully dissected from the 
airways and large vessels. The cell suspension was successively filtered (first through a 100 
µM then through 40µM mesh filter membranes and finally through a 20 µM filter paper) to 
obtain a single cell suspension and resuspended in 10ml of complete DMEM media. The cells 
were then incubated with biotinylated rat anti-mouse CD16/32 and rat anti-mouse CD45 
mAbs (specific leukocyte antibodies) for 30 min at 37oC. After this period, cells were washed 
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and incubated with streptavidin-linked MagneSphere Paramagnetic Particles for 30 min at RT 
with gentle rocking, followed by magnetic separation of contaminating leukocytes for 15 min. 
The purity of freshly isolated mice primary alveolar epithelial cells (AECs) in the supernatant 
was always >90% (assessed by trypan blue dye exclusion). Cells were then seeded on 24-well 
cell culture plates at a density of 4x105 cells/well and grown to 90% confluence for 2 days 
with complete DMEM media. On day 2 cells were washed and serum starved with 0.2% FCS 
and left until day 3, upon which they were submitted to virus infection, as described above.  
 
2.2.2.3. Storage of cell cultures 
For freezing; cells were washed with 1x PBS and 5ml of 1x trypsin-EDTA was then added. 
They were then incubated at 37°C with 5% CO2 and 95% humidity and left until cell 
detachment, after which 5ml complete media was added. Cell suspensions were then 
centrifuged at 350 g (Megafuge 1.0R, 1000 rpm), 4°C for 5 min. The cell pellet was gently 
resuspended with 1ml freeze medium (90% complete DMEM and 10% DMSO) and 
transferred into cryotubes. These were set into a styropore box and left to freeze gradually in 
the -80°C freezer. The DMSO prevents ice crystal formation and allows the cells to remain 
intact. After 24 hours, cells were transferred into liquid nitrogen where they can be kept for a 
longer period of time. 
For thawing; cells were removed from liquid nitrogen and immediately transferred into a 37°C 
water bath for 5 min. Cells were then resuspended carefully and transferred into a cell culture 
flask filled with 19ml of corresponding medium (such as complete DMEM for mammalian 
cells). After 24h cells will have reached 100% confluency and should be passaged for further 
propagation. 
 
2.2.3. Infection of cells 
The virus inoculum was prepared by adding the according amount of virus stock to a certain 
volume of PBS/BA/P/S/Ca2+Mg2+ depending on the desired multiplicity of infection (97) used 
for experiment. Confluent cells in 3.5 cm dishes were washed with 1x PBS++ and 200 µl of 
virus inoculum was laid on top by creating bubbles in the middle of dish, to ensure a 
consistent virus distribution. The cells were further incubated at room temperature for 1 hour, 
after which the inoculum was removed by aspiration and 2ml of DMEM/BA media was 
added. Cells were then further incubated at 37°C with 5% CO2 for the desired time points.  
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The calculation of moi was done as follows: 
 
2.2.4. Preparation of cell lysates for Western blot analysis 
After certain time of infection or transfection, cells were washed with cold 1x PBS++. 
Thereafter another 1ml of cold 1x PBS++ was added to the cells, then they were scraped off 
and transferred into eppendorf cups. Centrifuge at 13,000 rpm (Biofuge 13, 25,000 g) for 1 
min and the cell pellet resuspend in 75 µl lysis buffer. The lysis was done by incubating cells 
for 20-30 min on ice with vortexing every 5 min. The lysed cells were centrifuged at 13,000 
rpm (Biofuge 13, 25,000 g), 4°C for 15 min. The supernatant was finally transferred into new 
eppendorf cups and stored at -70°C till required. 
 
2.2.5. DNA-transfection of eucaryotic cell cultures 
2.2.5.1. Transfection of adherent 293T cells and MDCK cells  
The day before transfection, 293T or MDCK cells were split 1:2 into a new flask to promote 
cell growth. The next day the cells were seeded in 3.5 cm dishes to grow to approximately 
90% confluence over night for the transfection. DNA and Lipofectamine 2000 mix were 
prepared as follows: some amount of DNA (in µg) was diluted in OPTI-MEM reduced serum 
medium (final volume is 100 µl) and mixed gently in a 5ml polystyrene round-bottom tube. 
Some amount of Lifectamine 2000 (2µl of lipofectamine 2000 per µg DNA) was mixed and 
diluted in OPTI-MEM (final volume is 100 µl) in another 5ml polystyrene round-bottom tube, 
mixed gently and incubated not longer than 5 min at room temperature. The diluted 
Lipofectamine 2000 was added to the tube containing the diluted DNA, then mixed gently and 
incubated for 20 min or longer (no more than 6h) at room temperature to allow forming of the 
DNA-L2000 complexes. During the complexes were formed, culture medium was washed 
with 1xPBS and refreshed with 800 μl of new medium without antibiotics (DMEM+10% 
FCS). The DNA-Plus-Lipofectamine Reagent complexes (total 200 µl volume) were added 
dropwise into the dish containing fresh medium. The cells were incubated at 37oC at 5% CO2 
for 6h. Thereafter, the media containing DNA-Plus-Lipofectamine Reagent complexes was 
removed and replaced with 2 ml of complete DMEM media. The cells were further incubated 
at 37oC at 5% CO2 for 24-48h.  
 
1000 µl 
Virus titer [PFU] moi x cell amount in the culture 
X µl virus 
= 
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2.2.5.2. Transfection of suspended 293T cells 
The day before transfection, 293T cells were split 1:2 into a new flask to promote cell growth. 
On the day of transfection, confluent cells in 75 cm2 culture flask were washed with 1x PBS, 
detached by 5ml Accutase I and incubated at 37°C for 15 min. During incubation time, DNA 
and Lipofectamine 2000 mix were prepared as mentioned section 2.2.5.1. After cell 
detachment, 5ml medium without antibiotics (DMEM with 10% FCS) was added into the 
flask, the mixture was transferred into a 15 ml Falcon centrifuge tube and subsequently 
centrifuged at 1,000 rpm (Megafuge 1.0R, 350 g) for 5 min. The supernatant was removed by 
aspiration, then the cell pellet was resuspended by adding 7ml medium (DMEM with 10% 
FCS). 800 µl of cell suspension was mixed with 200 µl of DNA-L2000 complexes and 
reseeded onto 3.5 cm dishes. The cells were incubated at 37oC with 5% CO2 for 6 hours, then 
1ml of media (DMEM with 10% FCS) was added. After 24h post tranfection, the media 
containing DNA-L2000 complexes was replaced with 2ml of complete DMEM medium. 
 
2.2.5.3. RNP reconstitution assay 
2.2.5.3.1. Transfection of adherent cells to do CAT assay after RNP reconstitution assay 
1.2µg of DNA mixture of four expression plasmids encoding the PB1, PB2, PA and NP 
proteins (in the ratio of 1:1:1:2) from PR8, FPV and GD virus respectively, and 2.0 µg of 
pPolI-CAT-RT (carrying the human polI-promoter), together with either empty vector pcDNA 
3.0 (4.0 µg) or pcDNA-NS1 (4.0 µg) from PR8, FPV and GD virus respectively were 
transfected according to section 2.2.5.1.  
 
2.2.5.3.2. Transfection of suspension cells to do primer extension assay after RNP 
reconstitution assay 
1 μg of each of relevant plasmids including pcDNA-PB1, PB2, PA and NP from FPV and 
pPolI-FPV-NA-RT as reporter gene, together with either empty vector pcDNA 3.0 or pcDNA-
NS1 or pcDNA-NS2 from FPV, GD, VN and Ma virus were transfected according to section 
2.2.5.2. Cells were harvested 48h post transfection or at the time points indicated.  
 
2.2.6. Chloramphenicol Acetyl Transferase ( CAT) assay  
The principle for CAT assay was shown in Fig 2.2. 
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2.2.6.1. Preparation of cell extracts 
Cells were washed with 1xPBS++
 
and cells were scraped in 500 μl 1xPBS++ and transferred in 
new eppendorf (on ice). Cells were centrifuged at 3000 rpm in a microcentrifuge (Heraeus, 
Germany) at 4°C for 1 min. Pellet was resuspended in 100 μl of 0.25M Tris-HCl (pH-7.4). 
Resuspended pellet was incubated for 2 min in liquid nitrogen followed by 5 min incubation 
at 37°C in water bath. This process was repeated for two more times and centrifuged at 3000 
rpm for 1 min at 4°C. 100μl supernatant, which is the enzyme extract, was transferred into a 
new eppendorf on ice and was used for CAT assay ((Invitrogen, USA) or was stored at -70°C. 
 
 
 
Fig. 2.2: The principle of CAT assay: CAT, a bacterial gene to neutralize the antibiotics chloramphenicol by 
acetylating the drug at one or two hydroxyl groups. Cell lysis containing CAT enzyme are simply incubated with 
the fluorescent substrate and acetyl CoA at 37°C,  ethyl acetate is added to terminate the reaction and to extract 
the fluorescent substrate and its acetylated derivatives, which are then resolved by thin layer chromatograph 
(TLC, Invitrogen). Brightly fluorescent, well-separated spots can be visualized with a hand-held UV lamp. To 
quantify CAT activity, a laser scanner typoon (GE healthcare) is used.  
 
2.2.6.2. Determination of relative protein amount 
A 5 μl sample from the cell lysate was taken to measure the relative protein amount and 
mixed as followed: 
5 μl sample 
200 μl Bio-Rad protein assay buffer 
800 μl ddH2O 
The relative concentration of protein was calculated by the measurement of the absorbance at 
the wavelength 595 nm in a DU-70 spectrophotometer (Beckman). According to the indicated 
absorbance, the protein concentration of different samples could be calculated by standcurve 
%
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derived from BSA standards or compared between samples by normalizing the lowest 
concentration to 1. 
 
2.2.6.3. Chloramphenicol reaction 
Running chamber was set up one day before Chloramphenicol reaction. 26ml of methanol and 
174ml of chloroform (13:87) was mixed for running buffer, and then running buffer was 
poured into the chamber and covered with a lid for overnight to generate a stable air gas phase.  
50 μl of each prediluted enzyme (1:10, 1:100 and 1:1000) extract was incubated with 20 μl 
(4mM) AcCoA and 5 μl BODIPY (Invitrogen). It was mixed properly and this 75 μl reaction 
mixture was incubated at 37°C for two and a half hours in a water bath. Thereafter, 500 μl of 
ethyl acetate was added and mixed, the mixture was vortexed vigorously for 5 min and then 
centrifuged at 13000 rpm for another 5min. Aftermath, two phases including upper ethyl 
acetate layer (450 μl) and lower water layer were created. Ethyl acetate layer was transferred 
into new eppendorf (with holes made in the lid) and were dried with speed vac machine 
(Savant) for 25min. 
 
2.2.6.4. Loading samples on TLC plate 
The dried pellet was dissolved with 20 μl ethyl acetate and was loaded in the form of little 
dots on TLC plate with the help of air supply. Air supply helps minimizing spread of ethyl 
acetate on TLC plate during sample loading. TLC plate was placed a little higher than the 
level of pre-equilibrated running buffer in an inclined position. The spots were migrated up by 
capillary action until the solvent reached the top of the TLC sheet (around 30min). Then it 
was stopped and allowed to dry. Later, the products (acetylated chloramphenicol) and the 
unacetylated substrate were visualized as a light green color spot on the chromatogram in UV-
light (as Fig. 2.3.). The plates were scanned by Typhoon 9200 (GE Healthcare) and the spots 
were quantified and calculated (as Fig. 2.3.) by GenQuant software (GE Healthcare).  
 
2.2.7. Generation, amplification and purification of NS reassortants of H7-type highly 
pathogenic avian influenza virus  
293T cells in 35 mm diameter dishes were transfected with 12 plasmids (5 μg DNA in total) 
according to section 2.2.5.1. For the generation of wt FPV, 1.2 μl (1μg/μl) of the protein 
expression plasmids (pHMG-PB1, pHMG-PB2, pHMG-PA and pHMG-NP) were transfected 
in a ratio of 1:1:1:2 along with 3.8 μl (1μg/μl) of the polI plasmids (pPolI-FPV-PB1, FPV-
PB2, FPV-PA, FPV-NP, FPV-HA, FPV-NA, FPV-M and FPV-NS) in a ratio of 
 2. Materials and Methods 
 
 52
1:1:1:1:2:2:1:1. To generate the reassortant viruses carrying different NS segments (GD-NS, 
VN-NS and Ma-NS), the pPolI-NS FPV plasmid was substituted by the polI-NS plasmids of 
GD, VN or Ma.  
At 24 h after transfection, the transfection mixture was removed and the cells were incubated 
with 8ml of fresh medium, which was replaced daily for 4 days. The harvested medium from 
transfected dishes was screened for rescued influenza virus by observation of liquid CPE and 
plaque assay on MDCK cells according to the section 2.2.8.1. The progeny viruses were 
amplified on MDCK cells in 75mm flask and continued for 3 round of Plaque purification 
according to section 2.2.8.1 to purify the viruses. The purified viruses were then amplified and 
titrated on MDCK cells by Foci assay according to section 2.2.8.2 and stored at -70°C. The 
generation of all viruses was carried out using biosafety level 3 procedures. 
 
2.2.8. Analysis of infectious virus titers  
2.2.8.1. Standard plaque assay 
MDCK cells were seeded on 3.5 cm dishes one day before and grew to 100% confluency. The 
cells were washed once with 1x PBS++, then 100 µl of virus dilution was laid on the cells. The 
cells were incubated at RT for 1h. During the incubation, 2% Oxoid agar was melted and 
incubated alongside at 42oC in a water bath. DMEM/BA medium was also incubated in a 
37oC water bath. After one hour, the inoculum was removed from the dishes, 2% oxoid agar 
was mixed with DMEM/BA (and the other solutions, as describe in section 2.1.9.). 2ml 
mixture was given immediately to every plate using a sterile plastic pipette. When the agar 
became solid, the dishes were inversely laid in a 37oC, 5% CO2 humidified incubator. 
Depending on the virus type, normally after 2 or 3 days plaques were seen on the dishes. Then 
the agar was removed from the dishes with a spatula. Cells were stained with coomassie 
brilliant blue (1ml/3.5 cm plate) at room temperature for 5 min, and then the plates were 
washed gently with tab water. Plaques were counted at different dilutions and the total amount 
of plaques was calculated by the following formula: 
PFU/ml  number of plaques  volume factor  dilution factor 
Volume factor: PFU (Plaque forming unit) is related to 1ml. If a dish was infected with 100 µl 
viral dilution solution, the factor is 10. 
2.2.8.2. Immunohistochemistry (MC Foci assay) 
Virus dilutions were made in the 96 well microtiter plates with U-form bottom. First 180 µl of 
virus dilution solution was pipetted into each well and 20 µl of the virus stock was added into 
the wells of the first row. The virus dilution (200 µl) was mixed by up and down pipetting and 
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20 µl of it was transferred into wells of the second row. The same steps were repeated up to 
the last row to get 10-1 to 10-8 dilution series. 
MDCK cells were seeded in 96-well plates and grown over night at 37°C with 5% CO2 so that 
they were 90% confluent on the day of infection. The cells were washed once with 1x PBS++, 
then infected with 50µl of virus dilution and incubated at room temperature for 1 hour. Virus 
inoculum was aspirated and 150µl methylcellulose media was added into each well. The plate 
was placed at 37°C with 5% CO2 for 30 or 48 hours depending on the virus strain. After the 
incubation, methylcellulose media was removed by aspiration. Cells were washed twice with 
1x PBS++ and fixed, as well as permeabilized, with 330µl/well of 4% PFA/1% TritonX-100 in 
1x PBS++ overnight at 4°C or alternatively for 1 hour at RT. Afterwards cells were washed 
and three times with 1x PBS/0.05% Tween20 and incubated with 50 µl of primary antibody 
(anti NP-mAb, 1:6000 diluted in PBS++/3% BSA) for 1h at room temperature. After aspirating 
the primary antibody dilution, cells were again washed three times with PBS/0.05% Tween20, 
followed by secondary antibody  incubation (Horse Radish Peroxidase (HRP)-conjugated anti 
mouse, 1:1000 diluted in PBS++/3% BSA) for 45 min at room temperature. Cells were washed 
40 µl of AEC staining kit solution (section 2.1.10) was used and was added into each well and 
placed at room temperature for 30-60 min. The AEC (3-Amino-9-ethylcarbazole) Staining Kit 
is used for staining peroxidase labelled compounds in immunohistochemistry or 
immunoblotting techniques. AEC produces an insoluble end product which has a red colour. 
Red stained foci were observed under microscope, wells were washed with normal water to 
remove the rest of salts and air dried at room temperature. After drying, the plates were 
scanned using the Canonscan 9900F (Canon) at 1600 dpi and virus foci counted. The viral 
titre was determined as follows: 
 
FFU/ml = number of foci x volume factor x dilution factor 
 
Volume factor: FFU (Foci forming unit) is related to 1ml. If a dish was infected with 50 μl 
viral dilution solution, the factor is 20.  
One foci was considered when more than 3-5 adjacent cells were stained in one particular 
area, as opposed to single cell staining which would probably mean, that the cell had not 
produced an infectious virus. 
 
2.2.8.3. Immunohistochemistry (Avicel Foci assay) 
Compared to MC foci assay with 150µl methylcellulose media., the incubation time for the 
foci forming was shorten to 20-30h in avicel foci assay with 150 μl 1.2% Avicel medium 
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overlay because low viscousity Avicel allowed higher mobility of virus particles. The rest of 
the procedure was the same as in section 2.2.8.2.  
 
2.2.9. Haemagglutination (HA)  
Red blood cells should be taken from Specific Pathogen Free (SPF) chickens. If SPF chickens 
are not available, blood may be taken from normal chickens that are shown to be free from 
antibodies to avian influenza viruses. Firstly about 20-30ml fresh chicken blood was 
transferred to a 50ml sterilized falcon centrifugation tube containing 10ml of 3.7% sodium 
citric acid. The RBCs was washed by filling the tube to 50ml with cooled PBS++ and 
centrifuged at 1,500 rpm (Megafuge 1.0R, 700 g) at 4oC for 10 min. The supernatant above 
the RBC-fraction containing serum, white blood cells and fat was carefully removed by 
aspiration, and then RBCs pellet was washed again with cooled PBS++ and centrifuged as 
mentioned above. This washing step was repeated twice. Finally the pellet of RBCs was 
diluted to 0.5% (v/v) with cooled PBS++ for haemagglutination assay. 
50 µl PBS++ was dispensed into each well of a plastic V-bottomed microtitre plate (96 wells), 
then 50 µl virus suspension (for example, cell culture supernatant) was placed in the first well. 
Two-fold dilutions of 50 µl volumes of the virus suspension were made from well #1-#12 in 
each row (left to right), subsequently 50 µl of 0.5% chicken RBCs was dispensed to each 
well. The mixture of every well was mixed by tapping the plate gently and then the RBCs 
were allowed to settle for about 30-60 min at 4oC. The Haemagglutinating Units (HAU) are: 
2x, where X is the number of the last well without tear-shaped streaming. 
 
2.2.10. Confocal laser scanning microscopy and immunofluorescence assay (IFA) 
Confluent cells were trypsinized by 1x trypsin-EDTA, reseeded in the 3.5 cm dish containing 
sterile glass cover-slips (12 mm) and incubated at 37°C with 5% CO2. On the next day, the 
cells were confluent. After infection or transfection, the growth medium was removed from 
the culture dish at the indicated time points, and the cells were washed once with 1x PBS++, 
then the cells were fixed with 1ml 4% PFA in 1x PBS++ over night at 4°C. After fixation, cells 
were washed twice with 1x PBS++ and subsequently incubated with 1ml 1% Triton X-100 for 
45 min. Cells were then washed 3 x with PBS and incubated with 20 µl of the primary mouse 
anti-Flu A NP mouse (clone 1331) (1:200 dilution in PBS++/3% BSA) or Rabbit anti-GST-
NS1 polyclonal antibody (1:1000 in PBS/3% bovine serum albumin), kindly provided by T. 
Wolff, (Berlin, Germany) for each cover-slip for 1 hour at room temperature. Afterwards cells 
were washed three times as before, and further incubated with 20 µl of the secondary 
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TexasRed-labeled goat anti-mouse IgG (1:200 diluted in PBS++/3% BSA) or goat anti-rabbit 
IgG (1:200 diluted in PBS++/3% BSA)  for 1 hour at room temperature. The cells were then 
washed again three times and incubated with 20 µl DAPI (10mg/ml in PBS/3% bovine serum 
albumin, Roth) for 5 minutes. After a further three washes (as above) and an extra wash with 
ddH2O, the glass cover slip was fixed on a glass slide with Mowiol/DABCO overnight. 
Fluorescence was visualised using a TCS-SP5 confocal laser-scanning microscope (Leica). 
 
2.2.11. “In cell” western blot 
Confluent MDCK cells in 96-well plates were infected with 50 μl of the different recombinant 
viruses at an MOI of 1. After 1h the virus innoculum was removed and 150µl DMEM/BA/P/S 
was added and the cells were incubated at 37°C with 5% CO2. At  2h, 4h, 6h and 8h p.i., the 
cells were washed with 1×PBS and fixed with 330 µl/well of 4% PFA for 20 min, 
permeabilized by washing four times for 5 min each with 150 µl/well of 1% Triton X-100, 
and blocked with 5 ml PBS–5% nonfat dried milk. To detect NS1, NP, and extracellular 
signal-regulated kinase 2 (ERK2; loading control) cells were incubated for 2h at room 
temperature on a shaker with a first antibody, which was either polyclonal rabbit anti-NS1 
serum (anti-GST-NS1 9101 at 1:1,000; GST is glutathione S-transferase; T. Wolff), mouse 
anti-NP MAb (1:5,000; Abcam), mouse anti-ERK2 MAb (1:100; Santa Cruz), or polyclonal 
rabbit anti-ERK2 (1:100; Santa Cruz) serum diluted in PBS, 5% nonfat dried milk, 0.2% 
Tween-20. Thereafter, cells were washed four times for 5 min each with Tween washing 
solution (PBS, 0.5% Tween-20) and incubated for 1 h at room temperature in the dark with a 
second antibody (goat anti-rabbit IRDye 680 or goat anti-mouse IRDye 800 CW (both from 
Licor)) in PBS, 5% nonfat dried milk, 0.2% Tween-20. Finally, plates were washed again one 
time as described above with PBS, dried, and analyzed using the Odyssey Infrared Imaging 
System and application software package (Licor). For each time point six wells were 
analyzed. 
 
2.2.12. Western blotting (Semi-dry) 
2.2.12.1. Measurement of protein concentration (Bio-Rad protein assay) 
The Bio-Rad Protein Assay is based on the observation that when Coomasie Brilliant Blue 
G250 binds to the protein the absorbency maximum shifts from 450 nm to 595 nm. 5 µl of 
cell lysate (as described in 2.2.4. section) was added into diluted Bio-Rad Dye Reagent (1:5 
dilution of Dye Reagent concentrate in ddH2O). Mix well and after a period of 10 min, the  
relative protein content was determined by measuring the absorption at wavelength 595 versus 
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reagent blank (containing the lysis buffer only). This was done to apply an equal protein 
amount of all samples onto the SDS-PAGE gel. 
 
2.2.12.2. Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) 
The electrophoresis apparatus was assembled according to manufacturer's (Bio-Rad) 
instruction, and the resolving gel was poured in between the two glas plates. Leave a space 
about 1 cm plus the length of the teeth of the comb. Isopropanol or 100% ethanol was added 
to the surface of the gel to apply an even distribution along the gel surface. After the resolving 
gel was polymerized, isopropanol was removed and the stacking gel was poured on top of the 
resolving gel. Insert the comb and let the gel polymerise. 75 µl total containing protein of one  
sample (after determining the protein concentration) with 35 µl laemlli buffer containing 10% 
β-mercaptoethanol to reduce disulphide bonds were incubated for 5 min at 95°C  and cooled 
on ice for 1 min, then shortly centrifuged and the calculated amount was loaded into wells of 
gel. Rainbow protein marker (Roche, 2 µl marker + 8 µl laemlli buffer) was loaded as control. 
After running buffer was added to the chamber, a cover was placed over the gel chamber. 
Gels should be run at about 20 V/cm gel length. The negatively charged SDS-proteins 
complexes migrate in the direction of the anode at the bottom of the gel. Small proteins move 
rapidly through the gel, whereas large ones stay at the top. Proteins that differ in mass by 
about 2% can be distinguished with this method. The electrophoretic mobility of many 
proteins in SDS-polyacrylamide gels is proportional to the logarithm of their mass. 
 
2.2.12.3. Transfer membrane in "Semi-dry" electroblotter  
After the cell extracts were subjected to SDS-PAGE, the proteins were transferred by 
electroblotting onto a PVDF-Membrane, which was incubated before in 100% Methanol for 
2-3 min, and washed three times (5 min each) in ddH2O, then equilibrated in the transfer 
buffer for 2-3 min. On the layer of 2 blotting papers soaked with transfer buffer the PVDF-
Membrane was laid. The polyacrylamide gel and again 2 blotting papers soaked with transfer 
buffer were then placed on the PVDF-Membrane, making a "sandwich" (without any 
bubbles), and laid in "Semi-dry" Electroblotter. The current was set to 0.8 mA/cm2 for 90 min 
for transfer. 
 
2.2.12.4. Immunodetection of proteins 
After transferring the proteins, the PVDF-Membrane was washed for 5 min in 1x TBST 
buffer, then the membrane was blocked in blocking buffer for 2 hours at room temperature or 
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overnight at 4°C. There after the membrane was washed for 5 min in 1x TBST buffer, then 
incubated with the primary antibody (e.g. P-ERK monoclonal antibody, 1:500 dilution in 
blocking buffer) for 1 hour at room temperature. After washing three times (5 min each) in 1x 
TBST buffer, the membrane was incubated with the secondary antibody solution (e.g.: HRP-
conjugated anti mouse monoclonal antibody, 1:1000 dilution in blocking buffer) for 1 hour at 
room temperature. 
 
2.2.12.5. Enhanced chemiluminescence (ECL) reaction 
As mentioned above the membrane was washed three times (5 min each) in 1x TBST buffer 
and once in 1x TBS, then incubated for 1 min in ECL (enhanced chemiluminescence) solution 
which was prepared according to the manufactor (Amersham) between a glass plate and a 
clear plastic membrane. After 1 min, everything was laid into a photo cassette, and then a light 
sensitive film was placed on top of the membrane and exposed for 1.5-5 min or longer. The 
film was then developed. 
In order to detect the ERK2 protein (as a loading control), the attached antibody was striped 
from membrane by incubating with a 1:10 diluted “strong stripping solution” (Re-Blot Plus 
Western Blot Recycling Kit, Chemicon) for 45-60 min at 37°C. After washing with 1x TBST 
buffer for 5 min, the membrane was incubated in blocking buffer for 2 hours at room 
temperature. Then it was washed for 5 min in 1x TBST buffer and incubated with the anti 
ERK2 monoclonal antibody (1:1000 dilutions in blocking buffer) solution for 1 hour at room 
temperature. Subsequently the membrane was washed three times in 1x TBST buffer and 
washed once in 1x TBS, then incubated for 1 min in ECL solution and proceeded as 
mentioned above. 
 
2.2.12.6. Quantification of protein bands 
Protein bands exposed on the film were scanned (Canoscan LiDE 30/N1240U) at 800 dpi and 
the picture was saved in grey scales as TIFF file. The intensity of protein bands was 
densitometrically determined by means of PC-BAS software. These steps were done for P-
ERK bands as well as ERK2 bands. The lowest value of ERK2 band, which was set to one, 
was divided by each value of ERK2 bands to get a factor for each according P-ERK band 
value. This calculation was done to normalize the amount of P-ERK by the amount of ERK-
protein loaded. 
 
 
 2. Materials and Methods 
 
 58
2.2.13. Primer extension 
2.2.13.1. Isolating RNA (Trizol Method) 
To isolated  total RNA from infected cells, confluent MDCK cells in 35mm dishes were 
infected with different recombinant virus at MOI=1 in triplicates. The total cellular RNA was 
extracted with Trizol reagent (Invitrogen) at different time point post infection (2h p.i., 4h p.i., 
6h p.i. and 8h p.i.) as followed: 
The medium for transfected or infected cells in 35mm dishes was aspirated and 1ml of Trizol 
was added into the dishes, after 5min incubation at room temperature, Trizol was stired with 
P1000 tip until all the cells are suspended. Then the solution was transferred into an reaction 
tube and was incubated at room temperature for 10min. To each reaction tube 200 μl of 
chloroform was added and mixed properly and incubate for 5 min at room temperature with 
occasional shaking. Later the tubes were centrifuged for 20 min at 4°C at 13000 rpm. The 
upper phase (app. 0.6ml) was transferred later into fresh RNAase free reaction cup. 0.5ml 
isopropanol was added to this upper phase supernatant and mixed properly and incubated at 
room temperature for 10 min. Afterwards centrifuge at 13000 rpm for 20 min at 4°C. The 
supernatant was removed carefully and 1ml of ethanol was added to the pellet and centrifuged 
at 13000 rpm for 5-10 min at 4°C. Without dislodging the pellet, alcohol content was 
discarded and pellet was air dried for 5-10 min and dissolved in 30 μl of RNAase free (DEPC) 
H2O and used directly for the experiment or frozen at -70°C. 
2.2.13.2. Primer labeling 
The gene-specific primers used were as followed: NA vRNA: 5´-
GTAGCAATAACTGATTGGTCG-3´ (expected size 134nt); NA mRNA and cRNA: 5´-
GCGCAAGCTTCATGAGATTATGTTTCC-3´(expected size of cRNA 160 nt and mRNA 
approx 169-174 nt); NP vRNA: ATGATGGAGAGTGCCAGACC 3' (expected size of band 
181 nt); NP mRNA and cRNA 5ʹ- ACCATTCTCCCAACAGATGC 3' (expected size of    
cRNA 121 nt and mRNA approx 135 nt). On receiving,  the primers should be diluted into the 
concentration of 10pmol/ µl.  
Labeling reaction:            Primer 10pmol/µl    1µl 
DPEC H2O                           6µl 
10x PNK Buffer (Roche)   1µl 
[γ-32P]ATP (6000 Ci/mmol, 10µCi/µl)      1µl 
PNK (T4 polynucleotide kinase, 10U/µl)    1µl 
            ------------------ 
                   10µl 
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Mixed well and incubated at 37°C for 1h in PCR thermoblock. After 1h incubation, This 10 μl 
mixture was transferred into new 1.5ml RNAase-free reaction cup and further 450 μl PN-
buffer (Qiagen Nucleotide removal kit) was added, mixed well and placed over the Qiagen 
Nucleotide removal column with the help of a pipette. The column was spun for 1 min at 6000 
rpm and the collection was discarded. The column was washed 2 times with 500 μl PE-buffer 
(Qiagen). Further spun down for 1 min at 6000 rpm and the collection was discarded followed 
by one more time spinning down for one minute at 13000 rpm to remove residual alcohol 
content in the column. Fresh 1.5ml RNAase free eppendorf tube was labeled clearly and the 
column was placed onto it. 40 μl EB-buffer (Qiagen) or DEPC H2O was added on the column 
and incubated for 2 min at room temperature. Finally the tube was centrifuged for 1 min at 
13000 rpm and the eluate (40 μl) was collected in the eppendorf. This can be stored at -20°C 
in isotope room. 
 
2.2.13.3. DNA-marker labelling 
Labeling reaction:             autoclaved dH2O    6.0µl 
1 Kb DNA Ladder (Roche marker IV) 1.0µl 
10x PNK Buffer (Roche)   1.0µl 
[γ-32P]ATP (6000 Ci/mmol, 10µCi/µl)           1.0µl  
PNK (T4 polynucleotide kinase, 10U/µl) 1.0µl 
                                                                ------------------ 
                   10µl 
Mixed well and incubated at 37°C for 1h in PCR thermoblock. After 1h incubation, This 10 μl 
mixture was transferred into new 1.5ml RNAase-free eppendorf tube and further 190 μl 3x 
DNA loading dye buffer is added mixed well and stored at -20°C in isotope room. Before gel 
loading, add the phosphorylated markers directly to the Loading Dye, heat at 95°C for 10 
minutes and then immediately load the markers onto the denature running gel. 
 
2.2.13.4. Reverse transcriptase 
Labelled primer-mix : mix the primers as follows according to the no. of samples  to be  
analyzed and always make surplus than the need. 
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For one sample:  
P32 labelled  Primer for vRNA (10mmol/µl)(µl) 0.25 µl 
P32 labelled primer for cRNA and mRNA (10mmol/µl) (µl) 0.25 µl 
P32 labelled primer for 5s rRNA100  (10mmol/µl) (µl) 0.25 µl 
Primer for 5s rRNA100 (cold) (10mmol/µl) (µl) 0.25 µl 
DEPC H2O (µl) 3 µl 
Total (µl) 4 µl 
 
For one reaction, 1.0µl of trizol-purified RNA was mixed with 4.0µl of primer mixture. 
After 3 min running at 95°C in PCR block, the tubes were placed on ice for 5min. 
During 5 min incubation time, the superscript mixture was prepared as followed: 
For one sample : 
5x RT buffer (Invitrogen) (µl) 2 µl
100mM DTT (Invitrogen) (µl) 1 µl
10mM dNTP (sigma) (µl) 0.5 µl
DEPC ddH2O (µl) 1.25 µl
Superscript  II (Invitrogen, 10 units/ µl )(µl) 0.25 µl
Total (µl) 5 µl
Superscript master mix was prepared as mentioned in the table above, and then pre-incubated 
at 45°C alongside with the primer-RNA mixture in a PCR block. When the RNA-primer 
samples reached to 45°C, 5μl of the Superscript mix was aliquoted into the RNA mix, then 
incubated for 1 hour at 45°C (for reverse transcriptase reaction), followed by incubation at 
70°C for 10 minutes (to inactivate the Superscript) and cold to 4°C. 
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2.2.13.5. Running the 6% 7M urea polyacrylamide gel  
During reverse transcriptase reaction, the 6% 7M urea polyacrylamide gel should be prepared 
as follows: 
                                           Urea                                21.0g 
10X TBE                5.0ml 
40% acrylamide               7.5ml 
                                                              ------------------
Autoclaved ion free water to                          50ml 
The above solution was mixed very well until the powder is dissolved. When the gel 
apparatus is ready, 0.5ml 10% APS and 0.05ml TEMED is added to the falcon tube and mixed 
quickly. The gel mixture was poured into the apparatus followed by 20min incubation at RT 
and was fixed in the gel tank. 
8μl of formamide mix containing 10mM EDTA, xylene cyanol (Sigma No: X-2751XC) and 
Bromophenol blue (Sigma, sodium salt) ACS reagent, No: B-7021BPB) was added to each 
samples and mixed, and heated to 95°C. 10μl of each sample was loaded on the gel. The gel 
was run at 1200V until the blue dye is approximately 3 cm  away from the bottom of the plate. 
When the gel run was finished, the glass plate was separated very carefully and the gel should 
stick to one of the glasses. The gel on the glass was wrapped into clingfilm and transferred to 
a cassette (BioMax Cassette 35 x 43 cm , cat 856 2381), then the intensifying screen was 
placed on top of the gel. In the darkroom, a Kodak® BioMax™ MS film (Sigma, Z363006 or 
Kozak MS-1 8294985) was placed between two layers of Intensifying screens (BioMax™ 
Transcreen®, Sigma, Z374318) and everything is placed on top of the gel . After that, the 
cassette was incubated at -80°C overnight or longer. To develop the film, the Cassette should 
be opened in dark room again and the film was put into film develop machine (Kozak). 
 
2.2.13.6. Quantification of cDNA bands from different viral RNAs and 5sRNA    
The gel on the glass plates was transferred to wattman-paper (right size) and was wrapped in 
cllingfilm (plastic foil side at the top). Then the gel was dried in vacuum drier for 90min. 
When the gel was dried, it was placed in the screen cassettes together with a image plate 
phosphor (Fuji Photo Film Co. Ltd. )the gel side should be facing towards the white side of 
screen) overnight. Next day the screen was scanned on a typhoon 9200 (GE Healthcare) and 
the bands were quantified using GenQuant software (GE Healthcare). 
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2.2.14. Tunel assay (in situ cell death detection kit)  
Extensive DNA degradation is a characteristic event which occurs in the late stages of 
apoptosis. Cleavage of the DNA may yield double-stranded, LMW DNA fragments (mono- 
and oligonucleosomes) as well as single strand breaks (“nicks”) in HMW-DNA. Those DNA 
strand breaks can be detected by enzymatic labeling of the free 3’-OH termini with modified 
nucleotides (X-dUTP, X = biotin, DIG or fluorescein). This method called “Terminal 
deoxynucleotidyl transferase dUTP nick end labeling” (TUNEL).   
MDCK cells grown on glass coverslips were infected with recombinant viruses at MOI= 1 for 
10h. Cells were washed with 1×PBS PBS, and fixed with 4% paraformaldehyde (PFA) in 
1×PBS (pH 7.4) over night at 4°C.  The samples were then washed twice with 1×PBS and 
permeabilised with 1% Triton X-100 in 0.1% sodium citrate on ice for 20 min. Cells were 
washed and incubated with 50µl reaction mixture (provided in the kit, Invitrogen) or the "no 
enzyme" control in 50µl label solution (provided in the kit, Invitrogen)  for 1h in the dark. 
After 3 washes with 1×PBS, cells were incubated with DAPI (10mgml-1 in PBS/3% bovine 
serum albumin) for 10 min in the dark. Finally, cells were washed twice and were fixed in 
Mowiol/DABCO. Fluorescence was visualised using a TCS-SP5 confocal laser-scanning 
microscope (Leica). 
 
2.2.15. IFN-beta enzyme linked immunosorbent assay (ELISA) 
IFN-beta concentrations were assessed using the human IFN-beta ELISA kit (Fujirebio) 
according to the manufacturer’s protocol. Briefly, confluent A549 cells in 3.5cm dishes were 
infected with the different recombinant virus at an MOI of 0.01, and at 24h p.i., 36h p.i. and 
48h p.i. 100 μl of supernatant was taken and added into 96-well plates coated with human 
IFN-beta IgG Fab fragments, together with standards, and incubated for 1h with shaking at 
RT. After 2 washes with washing solution, the human HRP-labeled IFN-beta antibody was 
added and incubated for 1h with shaking at room temperature. After 3 washes, the substrate 
solution was added to develop the color, followed by the stop solution (0.5M H2SO4) and the 
OD at 450nm was measured. 
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3. Results 
3.1. Generation and confirmation of the recombinant H7-type HPAIV with different NS 
segments from H5- and H7-HPAIV 
Reassortant influenza viruses in the genetic background of A/FPV/Rostock/34 (FPV, H7N1) 
were generated by reverse genetics. As mentioned in section 2.2.7, 293T cells were 
transfected with 4 plasmids expressing polymerase proteins, NP and 7 plasmids expressing 
vRNA of FPV-PB1, FPV-PB2, FPV-PA, FPV-NP, FPV-HA, FPV-NA, FPV-M, together with 
plasmids expressing vRNA of FPV-NS, the wild type A/chicken/FPV/Rostock/34 (FPV wt, 
H7N1) or with other NS segments from A/Goose/Guangdong/1/96 (GD, H5N1), 
A/Mallard/NL/12/2000 (Ma, H7N3) and A/Vietnam/1203/2004 (VN, H5N1) respectively, 
FPV NS GD, FPV NS VN and FPV NS Ma were generated. At 24 h after transfection in 293T 
cells, the harvested medium from transfected dishes was screened for rescued influenza virus 
by observation of liquid CPE and plaque assay on MDCK cells according to the section 
2.2.8.1.  
After three rounds of plaque purification, the recombinant viruses were confirmed by 
restriction enzyme digestion of RT-PCR products obtained from the NS vRNA. Additionally, 
the NS, HA, NA and PB2 segments from different recombinant viruses were amplified by 
RT-PCR and sequenced by GATC corp. The results showed that after three passages, the NS, 
HA, NA and PB2 were not changed. 
 
 
Fig3.1: Confirmation of different recombinant viruses by restriction enzyme digestion of RT-PCR 
products. RT-PCR products were incubated with restriction enzymes and separated on a 1.5%  agarose gel. The 
undigested RT-PCR product is shown as a control.  With Spe I, Ma NS1 gave two bands of 435bp and 455bp. 
With EcoR I, VN NS1 produced two bands of 226bp and 549bp. With Hae III, the GD NS was digested into two 
bands of 367bp and 523p. 
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3.2. Analysis of the NS1 and NS2 protein sequences of the recombinant viruses 
In order to investigate how allele B NS segments affected virus replication in mammalian and 
avian cells, two allele B NS segments from A/Goose/Guangdong/1/96 (GD, H5N1) and 
A/Mallard/NL/12/2000 (Ma, H7N3) were used (Fig. 3.2A). A/Goose/Guangdong/1/96 was the 
source of the HA and NA gene segments in the A/HongKong/483/97 (HK97) virus which 
caused the first cluster of confirmed human cases infected with avian influenza virus in the 
world (219). The original GD virus itself has become established in geese and formed a 
distinct lineage in southern China (220, 221). The sequence of the GD NS1 protein is very 
similar to that of the Ma NS1, differing by only 8 aa (Fig. 3.2B). Of interest are those 
differences found at position 41, which is reported to be important for dsRNA binding (117); 
position 166, which is implicated in the interaction with PI3K (175); and position 224, which 
is located in the PABII binding region (166). The other differences are located in 
uncharacterized regions.  
In order to investigate whether H5-sourced NS segments generally increase the replication of 
an H7N1 FPV, I chose the NS segment from A/Vietnam/1203/2004 (VN, H5N1), which, 
similarly to the NS gene from A/chicken/FPV/Rostock/34 (FPV wt, H7N1), belongs to allele 
A (Fig. 3.2A). This virus was isolated from a human in 2004 (220), and is therefore a more 
recently emerged H5N1 virus than the GD H5N1 strain. The VN NS1 protein is truncated at 
the C-terminus by 10 aa, and also contains a 5 aa internal deletion (Fig. 3.2B). As a 
consequence of the 10 aa C- terminal truncation, the VN NS1 protein lacks a PDZ domain 
(227-230aa) and PABII-binding region (223-230aa). The deletion of residues 80–84 found in 
VN NS1 was often seen in recent H5N1 strains and implicated in cytokine resistance but not 
virulence (222, 223). These residues are part of a flexible linker between the RNA binding 
domain (RBD) and the effecter domain, and thus their deletion may greatly alter the 
orientation or stability of the RBD, or both. The deletion could compact NS1 and might confer 
more stability to the RBD, possibly increasing dsRNA binding affinity similarly to the D92E 
mutation (224). 
Comparison of the NS2/NEP aa sequences of these viruses reveals that this protein is more 
conserved than NS1 (Fig. 3.2C).  The majority of differences are found between the two allele 
A and two allele B viruses; however there are 2 aa differences between the GD and Ma 
NS2/NEP proteins, and 6 aa differences between FPV and VN NS2/NEP. Here a single aa 
difference located at position 14 is in the nuclear export sequence (NES) which is suggested to 
be a Crm-1 binding site, while the remaining differences are in uncharacterised regions (62).  
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Fig. 3.2: Sequence comparison between different NS1 and NS2 proteins. A) Phylogenetic analysis of the 
NS1 gene of A/FPV/Rostock/34 (FPV, H7N1), A/Goose/Guangdong/1/96 (GD, H5N1), A/Vietnam/1203/2004 
(VN, H5N1) and A/Mallard/NL/12/2000 (Ma, H7N3) and their allele type. B) Alignment of the aa sequences of 
the four NS1 proteins with sequence identity coloured in black. The sequence comparison was performed using 
Lasergene 6.0 software. C) Analysis of the NS2 protein sequences of the recombinant viruses. 
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3.3. NS segments can change the plaque phenotype of reassortant FPV viruses  
In order to investigate whether the different NS segments altered the replication ability of the 
wt FPV virus, the plaque size of the different viruses was measured in MDCK, A549 and 
Vero cells by foci assay (Fig. 3.3).  The plaque diameters on MDCK cells were measured and 
are represented as a distribution curve (Fig. 3.3B). The reassortant virus FPV NS Ma 
produced similar sized plaques to wt FPV, while those of FPV NS VN were much smaller 
than wt FPV and those of FPV NS GD were much bigger. This indicates that the FPV NS GD 
virus has a propagation advantage in MDCK cells compared to the other three viruses. In 
contrast, the FPV NS VN virus seems to replicate less efficiently in MDCK cells compared to 
the other viruses. The same phenotype was seen on A549 and Vero cells (Fig. 3.3C). 
 
 
Fig. 3.3: Plaque phenotype of recombinant FPV viruses in different mammalian cells. A) Foci assay 
showing plaque sizes.  MDCK cell monolayers were infected with the different recombinant viruses and stained 
with a monoclonal antibody against NP.  B) Distribution curve of the average plaque diameters.  50-78 plaques 
of each recombinant virus were measured. C) Plaque phenotype of recombinant FPV viruses in A549 cells and 
Vero cells.  
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3.4. NS segments can change the infectious titre and the HA titre of reassortant FPV 
viruses 
Viral growth curves and the HA titres of the different viruses in mammalian cells and avian 
cells were also determined (Fig.3.4). In mammalian cells (MDCK), the viral growth curves 
demonstrate that FPV NS GD replicates to higher titres than FPV wt, while FPV NS VN and 
FPV NS Ma replicate to lower titres (Fig. 3.4, represented as lines). This shows that the NS-
segments of both H7- and H5-type HPAIVs can affect the virus replication efficiency of FPV 
in mammalian cells and confirms the results obtained from the plaque phenotypes. Although 
both the Ma- and GD NS segments are grouped in allele B, the differences in the infectious 
titres between these two viruses indicates that the effects of the NS gene on virus replication 
efficiency does not depend on the allele type. In addition, these results suggest that H5-
sourced NS segments do not necessarily increase H7-type HPAIV infectious titre, as both the 
GD- and VN-NS segments are from H5N1 viruses and only the FPV NS GD virus had an 
increased titre.   
In order to determine whether the NS segments could affect the propagation of FPV in host 
cells of different origin, virus growth curves in an additional three mammalian cell lines and 
two avian cell lines were analyzed (Fig. 3.4). Similar results to those found in MDCK cells 
were obtained for the mammalian A549, 293T and Vero cell lines.  The results in Vero cells, 
shown to have an IFN deficiency (225), suggests that virus propagation is not affected by the 
type 1 IFN response. However, in avian LMH and QT6 cells, the NS reassortants showed 
different growth curves, as the FPV wt, FPV NS GD and FPV NS Ma viruses had similar 
titres, while FPV NS VN had a significantly lower titre. The FPV NS VN virus is attenuated 
in both mammalian and avian cells while the FPV NS Ma and FPV wt viruses replicate as 
efficiently as FPV NS GD in avian cells, but less well in mammalian cells. I therefore 
conclude that NS segment reassortment can have an effect on aiding viruses to cross host 
barriers and this might affect host transmission. 
I also found that the HA titres of the viruses differed from the infectious virus titres (Fig. 2C, 
represented as bars), which may indicate that different NS segments can affect the formation 
of virus particles and change the ratio between defective particles and infectious particles. For 
example, at 48h p.i. FPV NS VN has the highest HA titre (virus particles titre) of the 
reassortant viruses, equivalent to that of FPV wt; however this virus has a much lower 
infectious titre than the wt virus in MDCK cells (Fig. 3.4).  FPV NS VN has a low titre also in 
the other mammalian and avian cell lines tested while it produces higher or similar HA titres 
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compared to the other reassortant viruses (Fig. 3.4), suggesting that this virus produces large 
numbers of defective particles.  
 
 
Fig. 3.4:  Viral infectious titre and HA titre of recombinant FPV viruses in mammalian and avian cell 
culture systems. Confluent monolayers of cells (as indicated) were infected with the recombinant viruses at an 
MOI of 0.01.  Supernatants were harvested every 12h p.i., and samples were titrated on MDCK cells. Results 
represent the average of three independent experiments. Virus growth curves (represented as lines) were 
determined by foci assays in different cells and measured in FFU/ml. HA titres (represented as bars) were 
determined using 1.5% chicken red blood cells and measured in HA units/ml. Results represent the average of 
three independent experiments 
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3.5. NS1 protein production level does not affect the virus infectious titer. 
In order to investigate whether the effect of NS gene exchange on the propagation of 
recombinant viruses was caused by differences in the NS1 protein expression levels, “in cell” 
western blots were performed (Fig. 3.5). I found that early in infection the FPV NS VN virus 
had higher levels of NS1 protein expression than the other viruses, however by later time 
points there were no significant differences.  The different properties of the recombinant 
viruses could therefore not be explained by different NS1 expression levels.  In addition, the 
effect of NS gene exchange on the expression of another viral protein (the nucleoprotein, NP) 
was investigated, and no significant correlations were observed.  
 
 
 
Fig, 3.5: NS1 and NP protein expression measured by in-cell western blot. Confluent MDCK cells in 96-well 
plates were infected with the different recombinant viruses at an MOI of 1. Cells were fixed at 2 hour intervals 
and an in-cell western blot using an anti-NS1 antibody and anti-NP antibody, ERK2 antibody (as control) 
followed by staining with goat anti-rabbit IRDye 680 or goat anti-mouse IRDye 800 CW (both from Licor) was 
carried out. Infrared Imaging System and application software package were used (Licor). For each time point 
six wells were analyzed.  
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3.6. NS1 protein localization does not correlate with infectious viral titre. 
NS1 contains two nuclear localization signals (NLS) and one nuclear export signal (NES), 
which are responsible for transport of the protein between the nucleus and cytoplasm. The 
NS1 protein can therefore be present in the nucleus, the cytoplasm or both (119, 226). The aa 
sequence comparison (Fig. 3.2) showed that the sequence of both the NLS1 (34-39aa) and 
NLS2 (216-220aa) are conserved between the four NS1 proteins, however the sequence of the 
NES (138-147aa) differs at three aa positions between the allele A and B NS1 proteins. 
Therefore, I investigated the localization of the NS1 proteins of the different reassortant 
viruses in both infected and transfected MDCK cells. At all time points of infection I found 
that wt FPV NS1 was predominantly nuclear, GD NS1 and Ma NS1 were predominantly 
cytoplasmic, while VN NS1 showed a cytoplasmic and nuclear localization (Fig. 3.6). There 
was therefore no correlation between the infectious titer of the reassortant viruses and NS1 
localization during infection. Interestingly, when NS1 localization was investigated in 
transfected MDCK cells after 24 hours, NS1 proteins of all viruses were located exclusively in 
the nucleus (Fig. 3.6). 
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Fig 3.6:  Immunofluorescence looking at NS1 protein localisation. A) MDCK cells were infected with 
recombinant viruses at an MOI of 0.1.  At 4h, 6h and 8h p.i. the cells were fixed for immunofluorescence 
analysis. Immunofluorescence was carried out using antibodies against the NS1 protein (200) and DAPI (blue) 
for the nucleus. 70-80% of confluent MDCK cells were tranfected with 2 µg of different NS1 respectively. B) At 
24h post transfection, cells were fixed for immunofluorescence analysis. Immunofluorescence was carried out 
using antibodies against the NS1 protein  and DAPI (blue) for the nucleus. 
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3.7. NS segment reassortment can affect viral replication and transcription  
In order to analyze whether NS segment exchange could affect the virus replication and 
transcription, NA and NP gene-specific primer extensions were performed. Briefly, MDCK 
cells were infected with the different viruses at MOI of 1.0 and RNA was harvested at various 
time points post-infection (2h interval), then the primer extension was performed in 
triplicates.  The principle of primer extension is shown in the Fig 3.7.1. The viral transcription 
and replication can be reflected by the amount of viral RNA species detected by primer 
extension. 
 
Fig 3.7.1: primer extension for detection of viral replication and transcription. As mentioned before, viral 
vRNA is replicated by a cRNA with full length copy into more vRNA (replication) and trancribed into viral 
mRNA primed by cellular 5’ cap primer from vRNA (transcription). These three viral RNAs are different in their 
ends. If two radioactivity labelled primers are used for reverse transcription (RT) reaction to detect vRNA and 
cRNA/mRNA, they will give products of different length. After separation on the 7M urea  6% PAGE sequence 
gel, the RT products can be quantified to show the amount of viral RNA species.  
 
The results (Fig 3.7.2) showed that NS segment reassortment could alter the kinetic curves of 
viral replication and transcription for the different viruses by NP segment specific primer 
extension.  I found that the FPV wt, FPV NS GD and FPV NS VN viruses show a similar 
accumulation of mRNA, peaking at 4h.p.i. and then decreasing, while the mRNA 
accumulation of FPV NS Ma peaks at 6 h.p.i. (Fig. 3.7.2B), indicating that FPV NS Ma had 
become a slower virus compared to other three recombinant viruses.  
The vRNA kinetic curve of FPV NS GD was similar to that of FPV NS Ma, while FPV wt 
and FPV NS VN seemed to have a slower kinetic. The amount of viral RNAs from all four 
different reassortant viruses was seen to increase continually. For the kinetic curve of viral 
cRNA, FPV wt, FPV NS GD and FPV NS VN showed similar cRNA amounts during the first 
replication cycle, while FPV NS Ma showed a different kinetic and peaked at 6h.p.i..   
When the relative accumulation of RNA species for the different viruses was compared (Fig. 
3.7.2 C), I found that the FPV NS GD virus always produced more vRNA, cRNA and mRNA 
compared to FPV wt at all time points analyzed, while the FPV NS VN virus produced similar 
levels. At different time intervals, it seemed that the NS reassortant viruses have different 
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production kinetics. At 4h p.i., the difference between FPV wt, FPV NS GD and FPV NS VN 
is bigger than at other timepoints. At 2h p.i., FPV NS Ma produced less viral RNA species 
than FPV wt, but at later timepoints, it produces slightly higher amounts of RNA products 
than FPV wt. The Ma NS segment can therefore increase the level of accumulation of RNS 
species but not as efficiently as the GD NS segment. For FPV NS GD at 8h p.i., the amount of 
viral vRNA was more than that of viral mRNA. 
 
3.8. The effect of NS segment on viral replication and transcription is not segment 
specific. 
In order to determine whether the effects on replication and transcription were segment 
specific, I also analyzed viral RNAs derived from the NA segment.  The results obtained (Fig. 
3.8) showed similar relative RNA accumulation levels compared to those obtained for the NA 
gene, indicating that the effect of NS segment exchange on the production of RNA species is 
not segment specific. Overall, these results suggest that the NS segment products play a role 
in the regulation of viral replication and transcription. 
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Fig. 3.7.2:  Comparison of the accumulation of viral RNA species during infection by NP gene-specific 
primer extension. A) Primer extension analysis.  MDCK cells were infected at an MOI of 1 and total RNA 
harvested at the time points indicated.  NP gene-specific primers were used in a reverse transcription reaction and 
the products analysed on a 6M urea gel. B) Quantitation of the accumulation of RNA species for each 
recombinant virus.  RNA levels were normalized using the 5S rRNA control and results represent the average of 
three independent experiments.  C) Quantitation of the accumulation of RNA species at each different time point.  
RNA levels were normalized using the 5S rRNA control and results represent the average of three independent 
experiments.  Levels of FPV wt RNA species were set to 1. 
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Fig. 3.8:  Comparison of the accumulation of viral RNA species during infection by NA gene-specific 
primer extension. A) Primer extension analysis.  MDCK cells were infected at an MOI of 1 and total RNA 
harvested at the time points indicated.  NA gene-specific primers were used in a reverse transcription reaction 
and the products analysed on a 6M urea gel. B) Quantitation of the accumulation of RNA species for each 
recombinant virus.  RNA levels were normalized using the 5S rRNA control and results represent the average of 
three independent experiments.  C) Quantitation of the accumulation of RNA species at each different time point.  
RNA levels were normalized using the 5S rRNA control and results represent the average of three independent 
experiments.  Levels of FPV wt RNA species were set to 1 
 
3.9. Expression of individual NS1 and NS2/NEP proteins affects the accumulation of 
viral RNAs in an RNP reconstitution assay  
Next I wanted to detect which protein encoded by the NS segment is responsible for the 
change in viral replication and transcription activity that I have observed in section 3.7 and 
section 3.8. An RNP reconstitution assay in which different NS1 or NS2/NEP proteins were 
individually co-expressed, alongside the polymerase and NP proteins and a viral RNA 
template, was carried out as decrypted in section 2.2.5.3.2. The principle of in vitro RNP 
reconstitution assay is shown in Fig. 3.9.1.   
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Fig 3.9.1:  Principle of RNP reconstitution assay for primer extension and CAT assay: The plasmid pPOLI-
CAT-RT (or pPOLI-FPV-NA-RT) contains the CAT open reading frame in minus sense flanked by the 
noncoding regions of the NS RNA segment of influenza A/WSN/33 virus (or FPV NA) segments. Expression of 
the influenza virus-like RNA is driven by a truncated human RNA polI promoter and ended by a sequence 
derived from the hepatitis delta virus genomic ribozyme (R). The other four plasmids express viral PB1, PB2, 
PA, and NP proteins with a CMV promoter. These proteins are able to amplify and transcribe the influenza virus-
like RNA expressed by pPOLI-CAT-RT or pPOLI-NA-RT into mRNA, resulting in the detection of CAT 
activity and NS RNAs for primer extension in transfected human 293 cells. The represented regions in  
theplasmid constructs are not drawn to scale. 
 
Having shown that NS segment exchange can affect the transcription and replication of the 
viral RNA, I set out to further investigate the role of individually expressed NS1 and 
NS2/NEP proteins on these processes. An RNP reconstitution assay was employed, in which 
the four different NS1 or NS2/NEP proteins were individually co-expressed with the FPV 
polymerase and NP proteins and a viral RNA template (227). The results show that the 
transient expression of both NS1 and NS2/NEP proteins affected the accumulation viral 
RNAs (Fig. 3.9.2). Expression of all NS2/NEP proteins resulted in an increase in cRNA 
 3. Results 
 
 77
compared to the negative control, consistent with a previous report (24) (Fig. 3.9.2B). 
However, the NS2/NEP proteins of GD, Ma and VN did not produce significant changes in 
the accumulation of viral RNAs compared to the FPV NS2/NEP, suggesting that this protein 
is not responsible for the differences in transcription and replication between the reassortant 
viruses. Expression of all NS1 proteins resulted in a decrease in the accumulation of all viral 
RNAs compared to the negative control (Fig. 3.9.2C). When compared to FPV NS1, GD NS1 
down-regulated the accumulation of mRNA, while the Ma and VN NS1 proteins had little or 
no effect. The differential effect of the GD NS1 protein on the accumulation of viral mRNA 
could indicate a role for NS1 in viral transcription and replication 
It has been reported previously that the NS1 protein can inhibit cellular mRNA processing 
through an interaction with CPSF30 (127, 165, 167) and PABII (166). In order to address the 
possibility whether viral polymerase proteins and NP in the RNP reconstitution assay 
expressed from polII promoter-driven constructs were affected by NS1 protein expression, I 
transfected cells with a pcDNA3.0-CAT reporter construct and pcDNA-GD-NS1. I  found that 
GD NS1 protein did not affect CAT protein expression (Fig. 3.9.2D), and therefore I conclude 
that viral protein expression from polII promoter-driven plasmids is unlikely to be affected by 
the NS1 protein. 
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Fig. 3.9.2:  Comparison of the accumulation of viral RNA species during RNP reconstitution by NP gene-
specific primer extension. A) Primer extension analysis. 293T cells were transfected with plasmids expressing 
the PB1, PB2, PA and NP proteins of FPV and FPV NA vRNA. Either empty vector or plasmids encoding the 
various NS1 or NS2/NEP proteins were co-transfected into the cells. Total RNA was harvested after 48 hours 
and analyzed by NA gene-specific primer extension. B) Quantification of RNA levels following expression of 
different NS2/NEP proteins. mRNA, cRNA and vRNA levels were calculated from three independent 
experiments and expressed as a percentage of the values in the presence of FPV NS2/NEP (which were set to 
100%). C) Quantification of RNA levels following expression of different NS1 proteins. mRNA, cRNA and 
vRNA levels were calculated from three independent experiments and expressed as a percentage of the values in 
the presence of FPV NS1 (which were set to 100%). D) CAT assay testing the effect of the GD NS1 protein on 
CAT expression. 293T cells were transfected with plasmids expressing CAT at different concentrations 
(pcDNA3-CAT, 0.05µg, 0.1µg, 0.2µg) and GD NS1 (pcDNA3-GD NS1, 4.0µg). After 48h, cell extracts were 
prepared and tested for CAT activity in a 1:10 dilution.  
  
3.10. NS1 could have different effects on different RNP complexes.  
In order to investigate the effect of different NS1 proteins on polymerase function, plasmids 
expressing polymerase proteins and nucleoprotein from either FPV, GD or A/Puerto 
Rico/8/34 (PR8, H1N1) viruses, together with a CAT vRNA reporter vector (227) and 
plasmids expressing different NS1 proteins (FPV, GD and PR8), were transfected into 293T 
cells. I found that the FPV and GD NS1 protein decreased the reporter gene expression in all 
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three virus systems (Fig.3.10). These results are in agreement with the observation from the 
RNP reconstitution assay (Fig. 3.9.2B) that the various NS1 proteins can decrease the 
accumulation of all viral RNA products. Surprisingly, the PR8 NS1 protein enhanced CAT 
expression in the homologous PR8 system, but not in the FPV or GD systems (Fig.3.10). 
Since it reached the CAT convertion plateau at the dilution of 1:10 for PR8 NS1 in the PR8 
system, I also did further dilutions, which showed PR8 could enhance CAT proteins 10-100 
fold than PR8 system without PR8 NS1 (data not shown). Taken together, these data suggest 
that the NS1 proteins may have an effect on the RNP complex to regulate transcription and 
replication without the help of other viral proteins.   
 
 
Figure 3.10: CAT assay to investigate the effect of  between various NS1 proteins on RNP complexes.  
293T cells were transfected with plasmids expressing the PB1, PB2, PA and NP proteins from FPV, GD or PR8 
viruses and pPolI-CAT-RT for vRNA expression together with either empty vector or plasmids expressing FPV-
NS1, GD-NS1 or PR8-NS1. At 48h post-transfection, cell extracts were prepared and tested for CAT activity 
(1:!0 dilution). 
. 
 
3.11. NS segment exchange alters RNP export 
Efficient nuclear export of RNPs is important for the production of infectious virus (19). In 
order to investigate whether the NS segment exchange affected viral RNP export patterns, NP 
localization was analyzed by immunofluorescence using an anti-NP antibody (Fig. 3.11A). At 
8h p.i. most FPV NP was located in the cytoplasm, as was that of FPV NS GD, while FPV NS 
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Ma and FPV NS VN showed a more nuclear localization. These results indicate that NS 
segment exchange can alter RNP export dynamics and suggest a correlation between rapid 
RNP export and higher infectious virus titres. 
It has previously been shown that virus-induced activation of the Raf/MEK/ERK (MAPK)-
signal transduction cascade is an essential prerequisite for efficient nuclear RNP export (228). 
Membrane accumulation of the viral haemagglutinin (HA) glycoprotein in lipid-raft domains 
seems to be an important trigger that coordinates this signal-induction event with packaging of 
new RNPs into progeny virions (229). Induction or inhibition of the cascade will increase or 
reduce progeny virus titers respectively (228, 230, 231). Therefore, I investigated the extent to 
which the viruses activated the MAPK-cascade by detection of activated ERK (P-ERK) (Fig 
3.11B). The highest level of phospho-ERK was detected for the FPV NS GD virus, followed 
by wt FPV, with lower levels detected for FPV NS Ma and FPV NS VN, correlating these 
results with the finding that the RNPs of wt FPV and GD NS viruses are transported more 
efficiently than those of the FPV NS Ma and VN viruses. 
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Fig. 3.11: Recombinant viruses show differences in the nuclear export of RNPs. A) Immunofluorescence 
showing RNP export of the different recombinant viruses. MDCK cells were infected with recombinant viruses 
at an MOI of 0.1 and at 8h p.i. stained with an anti-NP antibody (red) and DAPI (blue) for the nuclei. B) Cell 
lysates of MDCK cells infected with the different viruses at MOI of 1 were analyzed for ERK activation by 
western blot using a phospho-specific anti-ERK and an anti-ERK2 (control) monoclonal antibody. C) Graph 
showing ERK activation of by different recombinant viruses. MDCK cells were infected with recombinant 
viruses at an MOI of 1 and cell lysates were prepared at 4h, 6h and 8h.p.i. Samples were analyzed for ERK 
activation by western blot using a phospho-specific anti-ERK and an anti-ERK2 (control) monoclonal antibody. 
The relative ERK activation values of two independent experiments were normalized to the loading control 
(ERK2).  
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3.12. NS segment exchange affects IFN-beta levels 
In order to test the ability of the different NS1 proteins to counteract the host innate immune 
response, IFN-beta levels were measured by ELISA in A549 cells infected with recombinant 
viruses at an MOI of 0.01 at various time points (24h, 36h and 48h p.i.). I found that FPV NS 
VN induced the highest IFN-beta response at all time points compared to the other three 
viruses, followed by FPV at 24 and 36 h.p.i. (Fig. 3.12).  When these results are compared to 
the titres of the various viruses it can be concluded that in general the more IFN-beta induced, 
the lower the virus titre.  
 
 
 
Fig. 3.12: Recombinant viruses induce different levels of IFN-beta.  A549 cells were infected with the 
recombinant viruses at an MOI of 0.01.  Supernatants were harvested at 24, 36 and 48 h.p.i., and measurement 
were taken using an IFN-beta ELISA kit. Results represent the average of three independent experiments. 
 
3.13. Recombinant viruses induce different levels of apoptosis 
During the course of our experiments I observed that the FPV NS VN virus appeared to cause 
cell death in a different way than the wt FPV, FPV NS GD and FPV NS Ma viruses in MDCK 
cells. Cells infected with FPV NS VN rounded-up but did not detach from the dishes, while 
infection with the other three viruses resulted in the cells becoming detached. I hypothesized 
that the FPV NS VN virus was inducing a different level of apoptosis compared to the other 
viruses. In order to determine the extent of apoptosis induced in cells infected with the 
different viruses. A Tunel assay was used in which MDCK cells were infected and examined 
by confocal microscopy (232). The number of dead cells was counted in five random viewing 
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fields by the confocal microscope and the results were represented as a graph (Fig. 3.13). It 
was observed that the FPV NS VN virus induced the highest levels of apoptosis, followed by 
FPV NS Ma, FPV wt and FPV NS GD (Fig. 3.13B).  Reassortant viruses containing different 
NS segments therefore differ in their abilities to induce cell death. When the extent of 
apoptosis is compared to the infectious titres of the various viruses it can be concluded that 
the higher levels of apoptosis correlate with lower virus titres 
 
Fig. 3.13:  Tunel assay to detect levels of apoptosis induced by the recombinant viruses. A) MDCK cells 
were infected with recombinant viruses at an MOI of 1, and at 10 h p.i. the cells were fixed and permeabilized 
before being processed using the In-Situ Cell Death Detection Kit (Roche) according to the manufacturer’s 
instructions. The specimens were then examined by confocal microscopy.  Green dots represent apoptotic cells.  
B) Quantitation of the number of apoptotic cells.  The number of green cells in five random views was counted 
in three independent experiments. 
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3.14. Recombinant viruses show different ability to counteract apoptosis 
NS1 is reported to have both pro- and anti-apoptotic functions (174-176). It was suggested 
that NS1 contributes temporally to both ‘early’ suppression of apoptosis and ‘late’ induction 
of cell death. The anti-apoptotic functions are linked to PI3K/Akt signal pathway. PI3K 
activation, as determined by Akt phosphorylation, was shown to occur in the first 8 h 
of infection (176) and is caused by expression of the viral NS1 protein (174, 175). In order to 
see how our NS exchange affects the anti-apoptic possibilities of the reassortant viruses, I also 
measured the amount of phosphalated Akt. The result showed in the early timepoints, FPV wt 
induced more Akt activation than FPV NS VN, FPV NS GD and FPV NS Ma, but this has no 
correlation to the virus titer, implying that the anti-apoptotic function is not responsible for the 
change in propagation of the recombinant viruses. 
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Fig. 3.14:  Recombinant viruses show differences in Akt activation.  Confluent MDCK cells in 96-well plates 
were infected with the different recombinant viruses at an MOI of 1. Cells were fixed at 2 hour intervals and an 
in-cell western blot using an anti-phosphalated Akt antibody, Akt antibody (as control) followed by staining with  
goat anti-rabbit IRDye 680 or goat anti-mouse IRDye 800 CW (both from Licor)) was carried out. Infrared 
Imaging System and application software package were used (Licor). For each time point six wells were 
analyzed. 
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3.15. Recombinant virus titre is not correlated with PKR activation 
One of the prominent functions of the NS1 protein is the inhibition of PKR. Normally, 
accumulation of dsRNA, a typical replication intermediate of RNA viruses, will activate PKR. 
Activated PKR leads to the induction of IFN via activation of NF-κB by IKK (233) and 
phosphorylation of eIF2α (150, 155, 234). The initiation of this cellular mechanism prevents 
further virus propagation. In order to analyze the ability of the various recombinant viruses to 
down-regulate PKR, I investigated the extent of eIF2α-phosphorylation as an indicator of 
PKR activity. MDCK cells were infected with the recombinant viruses at an M.O.I. of 1 and 
cell lysates were analyzed by western blot using an antibody specific for phosphorylated 
eIF2α. Surprisingly, none of the viruses caused a significant increase in phosphorylated eIF2α 
levels, and thus PKR activation, compared to untreated cells (Fig. 3.15A).  In fact, infection 
with any of the viruses appears to lead to a decrease in levels of phospho-eIF2α at some time 
points compared to uninfected cells, suggesting that all of the viruses can inhibit the activation 
of PKR to some extent. There appears to be no strict correlation between the titres of the 
recombinant viruses and PKR activation. 
This evidence was supported by infection of PKR(+/+) and PKR (-/-) primary mouse lung 
alveolar epithelial cells (AEC) with the different reassortant viruses.  The cells were infected 
at an M.O.I of 0.05 and foci assays was carried out at 12h, 24h and 36 h p.i. I found that there 
were no significant differences in the titres of the recombinant viruses between PKR (+/+) and 
PRK (-/- cells) (Fig. 3.15B), again suggesting that the abilities of the different NS1 proteins to 
suppress PKR activation was not responsible for the differences in titres between the 
recombinant viruses.   
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Fig. 3.15:  Recombinant virus titre is not correlated with PKR activation.  A) PKR activity measured by 
eIF2α-phosphorylation. MDCK cells were infected with recombinant viruses at an MOI of 0.05, and cell lysates 
were analyzed by western blot using a monoclonal antibody specific for phosphorylated eIF2α at the indicated 
time points. The relative phospho-eIF2α levels from four independent experiments were normalized to the 
loading control (eIF2α) and to the levels of NP as a control for viral protein expression. B) PKR(+/+) and PKR (-
/-) primary mouse lung epithelial cells were infected at an M.O.I of 0.05 with the recombinant viruses and foci 
assays were carried out with the supernatants at 12h, 24h and 36 h p.i.   
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4. Discussion  
In this work, I showed that replacement of the NS segment of the A/FPV/Rostock/34 (H7N1) 
influenza virus with NS segments from a variety of other H5 and H7-type viruses resulted in 
changes in the viral characteristics in mammalian and avian cell culture. Characterisation of 
the viruses in mammalian cells revealed differences in the growth kinetics of the reassortant 
viruses compared to wt FPV and to each other. As mentioned in the introduction, H7-type 
HPAIV had out breaken in Europe for many times while H5-type HPAIV has started 
spreading from Asia to Europe. This may raise the risk for the reassortantments between H7- 
and H5-HPAIV and may raise a potential threat for pandemics as it could confer enhanced 
replication ability of a highly pathogenic avian influenza viruses in mammalians system..   
In order to elucidate how NS segment reassortment altered virus propagation, multiple aspects 
of the interaction between the reassortant viruses and the host were examined. On the virus 
side, viral replication, transcription and genome transport were examined; on the host side the 
known functions of the NS1 protein in counter-acting the host innate immune response and 
inducing apoptosis were studied.  
 
4.1. The effect of different NS segments on the replication of a recombinant HPAIV FPV 
is independent of NS allele, the virus subtype and the year the virus was isolated, but 
depends on host factors and the genetic background. 
A series of recombinant A/FPV/Rostock/34 (H7N1) viruses with NS segments from H5- and 
H7-types, and from both allele A and B, were studied. The trend in the replication kinetic (Fig 
3.3) for the four recombinant viruses in four types of mammalian cells showed: 1) no 
difference between different mammal origin cells (A549 cells and 293T cells are from human, 
MDCK originates from Canine and Vero cells from Monkey) at MOI of 0.01; 2) no difference 
between interferon (IFN) competent cells (MDCK cells, A549 cells and 293T cells) and IFN-
/β deficient cells (Vero cells), indicating IFN- /β may not significantly limit the replication 
of the four recombinant viruses in the multiple replication cycles in a cell culture system. 
Vero cells are interferon-deficient and can not secrete type 1 interferon when infected by 
viruses (235),  but it is not known whether Vero cells are defective in pathways and genes 
other than IFN- /β. The induction of an antiviral state can also occur in the absence of IFN 
signaling (236-240). From this aspect, I thought the production of Interferon in this case may 
just be an indicator of cellular antiviral status, and maybe other cytokines play a more 
important role. Additionally, in cell culture without other immunological cells such as DCs, 
NKs and Macrophage cells, the production of interferon can only induce neighbor cells to be 
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in an antiviral status, but it can not induce the adaptive immune response. Another possible 
explanation is that our recombinant viruses replicated very fast and one single replication 
cycle is about 6-8hs, which I determined from the kinetics of viral RNAs production. Also I 
detected that at 12 hours, the viruses nearly reached the plateau of the replication kinetics, 
while the interferon beta level induced by the recombinant viruses in A549 cells was still not 
detectable (Fig. 3.12.). This indicates that the IFN-beta may not response in time to limit the 
virus replication at early time points. (Generally, at 2h p.i., type 1 interferon will be secreted, 
but then it has to reach the effective amount) 
I found that the FPV NS GD virus, which contains an allele B NS segment, replicated more 
efficiently than the wt FPV virus (allele A) in both mammalian and avian cell culture systems. 
This is in agreement with a previous study that also demonstrated that this virus had higher 
pathogenicity in mice (212). Reassortment of this allele B NS segment therefore has the 
potential to result in the emergence of an HPAIV that could cause severe infection in 
mammals. However, the results presented here show that the general effect of NS exchange 
on the replication efficiency is independent of the genetic group, as the second virus with an 
allele B NS segment, FPV NS Ma, had a lower replication titre than wt FPV. As mentioned 
before, allele B NS segments are not found in mammalian IV in nature except that one that 
was discovered in equine infection  and which was believed to be also avian like origin. Also, 
a previous study showed that allele B NS segments decrease avian virus replication in 
mammalian (211). It seems that allele B NS segments are not compatible with mammalian 
infection in nature, indicating that allele B NS segments are linked to avian species. However, 
my results alarmed us and highlighted that allele B NS segments may also increase the 
virulence in mammalians. 
I also addressed the question of whether H5-sourced NS segments, particularly those from 
viruses that emerged after 1998, increased viral growth of an H7-type HAPIV in mammalian 
cells. In a study by Twu et al. (206), a series of reassortant A/Udorn/72 (Ud, H3N2) viruses 
carrying NS segments from A/Hong Kong/483/97 (HK97, H5N1), A/Brevig Mission/1/18 
(1918, H1N1) and A/Vietnam/1203/04 (VN04, H5N1) were generated. It was shown that the 
HK97 NS virus replicated less efficiently than wt Ud virus, while in contrast the VN04 virus 
replicated as efficiently as wt Ud, and it was therefore concluded that H5N1 virus NS genes 
selected after 1998 seemed to enhance the replication of influenza viruses in mammalian cells. 
However, in my study, I observed that the NS segment from the VN virus isolated in 2004 
decreased the replication of reassortant avian H7-type virus (FPV) compared to the wild type, 
while the NS segment from the GD virus, isolated in 1996, enhanced FPV replication and 
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increased the plaque size. These results show that H5-sourced NS segments do not necessarily 
increase the replication of avian IV and the year of emergence does not appear to play a role. 
It is possible that the same NS segment may have different effects on virus replication due to 
the different genetic contexts; for example in this study we used the avian FPV virus as the 
background while in the study of Twu et al. a human virus strain was used. Other studies also 
showed that NS segment of HK97 viruses conferred high pathogenicity virus in mice (223) 
and in pigs (222) when inserted into the PR8 background while reassortant Ud virus 
containing HK97 NS segment showed decreased replication efficiency in mammalian cells 
(206). 
The differences in replication between the different viruses in cells of mammalian and avian 
origin (Fig 3.4) suggest that the effect of NS segments on viral propagation is dependant on 
host factors. In avian LMH and QT6 cells, wt FPV, FPV NS GD and FPV NS Ma had similar 
titres while FPV NS VN had a significantly (2 logs) lower titre, whereas in mammalian cells 
FPV NS GD replicated to titres of almost 1 log higher than wt FPV and two logs higher than 
FPV NS Ma. The NS segments of GD, FPV and Ma originated from avian viruses, and 
therefore I speculate that they all could have a replication advantage in avian cells. Wild type 
FPV and FPV NS Ma replicated to lower titres than FPV NS GD in mammalian cells, 
suggesting that the GD NS segment may play a role in helping the virus cross the host barrier 
to mammals. In this context it should be noted that in a previous study, the NS segment of the 
1918 IV (H1N1) was set in the genetic background of A/WSN/33 (H1N1). The virus 
replicated well in tissue culture (MDCK cells) but was attenuated in mice as compared with 
the control viruses (241). It was therefore suggested that the attenuation in mice may be 
related to the human origin of the 1918 NS1 gene and that interaction of the NS1 protein with 
host-cell factors plays a significant role in viral pathogenesis. Taken together, for the effects 
exerted by the NS segment exchange it seems to be relevant from which host the donor strain 
was isolated and in which host the recipient is tested. 
 
4.2. NS1 localization and expression level is not correlated to the alteration of viral 
propagation 
In order to investigate whether the effect of NS exchange on the propagation of recombinant 
viruses was caused by differences in the NS1 protein expression levels, the individual 
expression rate was investigated (Fig.3.5). I found that early in infection the FPV NS VN 
virus had higher levels of NS1 protein expression than the other viruses, however by later 
time points there were no significant differences. The different properties of the recombinant 
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viruses could therefore not be explained by different NS1 expression levels. In addition, the 
effect of NS gene exchange on the expression of another viral protein (the nucleoprotein, NP) 
was investigated, and here also no significant differences were observed.  
In theory, newly synthesized NS1 is present in the cytoplasm, where it may be involved in 
inhibiting the type 1 interferon expression by binding to dsRNA or pppRNA, or inducing a 
pro-apoptotic or anti-apoptotic pathway. After synthesis, the protein is also transported into 
the nucleus where it interferes with the processing and export of cellular mRNAs (128, 144) 
(128, 133, 134, 145, 226).  Later, some NS1 will be reexported into the cytoplasm, where it 
may play a role in the regulation of the host anti-viral response and possibly in the 
enhancement of viral mRNA translation. It was shown that NS1 can bind viral mRNA and 
viral vRNA, which allows the possibility that the later export of NS1 protein is related to viral 
mRNA transport (242). The NS1 protein has many diverse roles in both the cytoplasm and 
nucleus of infected cells, and therefore at this stage I cannot exclude the possibility that the 
different localizations of the NS1 proteins studied may play a role in the downstream effects 
observed. 
Another report showed that all NS1 located in the nucleus of cells transfected with plasmids 
expressing NS1 protein. It was suggested that the NES of NS1 was specifically inhibited by 
the adjacent aa sequence in the effecter domain (124). In contrast, in IV-infected cells the 
NES of the NS1 protein molecules was unmasked, and a substantial amount of the NS1 
protein is exported in the cytoplasm. Since this unmasking only happened in infected cells but 
not uninfected cells, it was conluded in the report that it is  more likely that this unmasking 
resulted from specific interaction between another virus-specific protein or host factors 
induced/altered by infection and the NS1 protein. Here, I also checked the localization of the 
four NS1 protein expressed from transfected plasmids. The results of Fig. 3.6 showed all the 
NS1 proteins located in nucleus of transfected MDCK cells, which is consistant with the 
previous report (124). In infected cells, GD NS1 and Ma NS1 are localized more in cytoplasm 
than in the nucleus compared to FPV NS1 and VN NS1 at 4, 6 and 8h p.i.. For GD NS1 and 
Ma NS1, most is localized in cytoplasm at 4h p.i. while most of FPV NS1 and VN NS1 was in 
nucleus at 4h and 6h p.i.. Later more NS1 was transported into cytoplasm. Why these NS1 
showed different localization patterns and what it means is still not clear. I assume that GD 
and Ma NS1 may have exterted more functions in the cytoplam compared to FPV and VN 
NS1, which may lead to stronger limitation of host antiviral response, including IFN response 
and apoptosis in the cytoplasm. FPV and VN NS1 are located preferentially in nucleus and 
therefore maybe inhibit mRNA processing and mRNA export. As mentioned before (section 
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1,4.3), NS1 contains two nuclear localization signals (NLS) and one nuclear export signal 
(NES) responsible for their transport between nucleus and cytoplasm. Therefore NS1 can be 
present in the nucleus, or the cytoplasm or both (119, 128, 144, 162, 226, 243). The aa 
sequence comparison between my four NS1 (Fig 3.2) showed that the NLS1 (34aa-39aa) and 
NLS2 (216aa-220aa) are the same between the four NS1. NES differs in 3 amino acids. 
Maybe these three amino acids differences contributed to the different localization of the four 
NS1. 
NS1 accumulation in the nucleus has been reported to help the replication of IV (123) Here, 
although GD NS1 and Ma NS1 had the same patterns NS1 localization, they produced 
different virus titer. The results showed that there was no correlation between intra-cellular 
NS1 localization and virus titres, which means they may have different functions even they all 
localized in nucleus or cytoplasm.  
 
4.3. Molecular mechanisms of NS segments that could affect the propagation of FPV 
In order to investigate how the NS segment altered virus replication and virulence, multiple 
aspects of the interaction between the recombinant viruses and the host were examined.  On 
the virus side, viral replication and transcription and genome transport were examined; while 
on the host side the known functions of the NS1 protein in counter-acting the host innate 
immune response and inducing apoptosis were studied. The results of Fig.3.7 and Fig. 3.8 
clearly show that the NS segments plays a role in the differential regulation of viral replication 
and transcription between the viruses (214). I could show that the NS1 protein played the 
major role in this regulation through an indirect effect on the viral polymerase in infection, 
which might be independent of PKR activity (Fig. 3.15). Differences in the regulation of viral 
RNA production between the infection assay and the RNP reconstitution assay were observed, 
leading to the speculation that viral factors and/or host factors may mediate the interaction 
between NS1 and the RNP complex, and that such host factors could be induced or altered by 
virus infection. This speculation is supported by the differences in viral replication between 
cells of mammalian and avian origin (Fig 3.3). 
  
4.3.1. Effects of NS segments on the viral replication/transcription activity 
Other have shown that the virus carrying NS1 with C-terminally deleted forms  of NS1 (NS1-
81 and NS1-110) produced less vRNA, but the similar amounts of cRNA and mRNA 
compared to wt virus at restrictive temperature, indicating that the NS1 protein is involved in 
the replication process during infection (214). In this work, the results of Fig 3.7.2 and Fig 3.8 
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clearly show that NS segments play a role in the differential regulation of viral replication and 
transcription between the viruses. The C-terminus of the VN NS1 is truncated by 10 aa, but 
the results in Fig 3.9.2 show a similar vRNA and cRNA production for wt FPV and FPV NS 
VN. The GD and Ma NS segments affected both transcription and replication and enhanced 
the accumulation of viral mRNAs compared to wt FPV and FPV NS VN in infected cells. 
FPV NS GD enhanced the accumulation of vRNA, cRNA and mRNA at different time points 
compared to FPV wt, implying that the components of GD NS could be possibly involved in 
regulation of both the replication and transcription progress. FPV NS Ma produced less viral 
RNAs (vRNA, cRNA and mRNA) at early timepoints (2h p.i.), but later it produced more 
viral RNAs than FPV wt, suggesting that components of Ma NS segment have different 
regulation efficiency at different stages of the IV infection cycle. 
Interestingly, NS exchange against the FPV genetic background also changed the kinetic 
curve of viral RNA production. FPV wt, FPV NS GD and FPV NS VN show similar kinetics 
for all viral RNAs: viral mRNA peaked at 4 h p.i. and then decreased, which is consistent with 
the observation that viral mRNA can peak up from 2.5 h p.i. to 4.5 h p.i and becomes weaker 
later on (242). The peak and later decrease could indicate that virus started to switch from 
transcription to replication. Equal quantities of cRNA are found to be synthesized through out 
the infection cycles except that FPV NS GD produced a marginal increase of cRNA at 4h.p.i 
(32), which is consistent with the observation of Vreede et al (55). Concerning vRNA 
kinetics, the results show that during the whole infection cycle, vRNA continued to increase 
which is in agreements with the study of Robb et al. (216). However, compared to the other 
three viruses, FPV NS Ma showed peak time point at 6h p.i instead of 4h p.i., for cRNA and 
mRNA. Also cRNA and mRNA at 8h. p.i. showed just a little decrease compared to that of 
6h.p.i. The delayed peak of accumulation of mRNA suggests that NS segments can influence 
the time course of RNA synthesis. It seems that the components of the Ma NS segment 
interfere with the RdRp activity in the transcription and in the replication step from vRNA to 
cRNA, and maybe also in the switch from transcription to replication. 
It was reported that specific mutations at position 123 and 124 in the NS1 protein of the Ud 
virus regulate the time course of viral RNA synthesis: vRNA, viral mRNA and proteins for 
early genes and late genes are synthesized at high levels at very early times after infection 
(155). In order to investigate whether the regulation observed in my experiments does not 
only affect the early NP gene expression, the viral RNAs production for the late NA gene was 
also tested by primer extension (Fig.3.8). The kinetic curves for the NA segments showed a 
similar trend like those for NP, which indicates that the regulation of the segments was is 
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similar for early genes as well as for late genes, indicating a general effect of NS components 
was involved in regulation of viral RNAs accumulations. 
Although the results show that the gene products of the NS segment can affect transcription 
and replication activity of the viral RdRp, the mode of this interaction is still elusive. For 
example, which gene product of NS segment is responsible for this interaction? Is there any 
direct functional interaction between NS1/NS2 (NEP)  and viral RNP complex? In vitro RNP 
constitution experiments (Fig.3.9.2) demonstrated that both NS1 and NS2 (NEP) regulated the 
production of viral RNAs. All NS2 proteins down regulated slightly viral mRNA and 
unregulated cRNA accumulation (consistent with a previous report (216)) compared to the 
negative control, indicating that NS2 interferes with the replication step from vRNA to cRNA. 
Furthermore, NS2 did not change viral RNA production between different viruses 
significantly, implying that NS2 may not be the cause of the differences in viral RNAs 
production in infected cells. On the other side, the NS1 protein decreases the accumulations of 
viral RNAs compared to the negative control, this hint at the possibility that the NS1 is 
involved in the transcription and the replication step. Compared to the FPV NS1, the GD NS1 
decreased the accumulation of mRNA more, while the Ma and VN NS1 resulted only in a 
little or no change. This suggests that the difference in the regulation of replication and 
transcription during viral infection maybe caused by the NS1 protein. But still I cannot 
exclude that NS1, NS2 and viral RNAs from NS segments may cooperate in this effect. 
Both components (NS1, NS2) from the GD- and the Ma NS segments did not increase the 
accumulation of viral RNAs in the transient in vitro system in contrast to the increase in 
infected cells, indicating that the enhanced effect of NS prodcuts on the viral transcription and 
replication in infected cells might not be a direct effect and could depend on virus-induced 
host factors or other viral factors. It is not clear how NS1 affects the viral transcription and 
replication. Although, the viral RNP complex can direct viral transcription and replication 
without host factors (244), it was also reported that host factors might regulate or further 
enhance viral RNA transcription and replication in infected cells (245, 246). Additionally, the 
NS1 protein was reported to interact with the viral transcription–replication complex in vivo 
(213). If so, there must be other viral or host factors induced by the infection affecting this 
interaction. It was also shown that NS1 could counteract with some cellular factors which 
inhibits the viral replication and help the polymerase proteins dissociated from RNP complex 
for virus replication (247). Recently, the influenza A virus NS1 protein was reported to form a 
complex with CPSF-30 and the viral RNPs (215). Since CPSF-30 is present in both the 
infection and RNP reconstitution assays, this suggests that the interaction with CPSF-30 is 
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unlikely to be responsible for the different effects observed during infection and RNP 
reconstitution. In addition, our previous data showed that GD NS1 and FPV NS1 have similar 
binding affinities for the F2F3 domain of CPSF-30 (212). However, we cannot exclude that 
the macromolecular complex may also contain other host factors besides CPSF30-NS1A and 
RNP complex. From the results derived from RNP reconstitution assay, it can be assumed that 
NS1 inhibits the viral transcription and replication with or without the participation of other 
viral factors or host factors. However, in infection, the interaction between NS1 and some 
viral factors or some host factors induced/altered by infection may modify this inhibition and 
thereby regulate transcription and replication.  
It has become clear in previous research that the host cell nucleus provides important 
functions for the vRNA synthesis machinery. In fact, it is likely that the full spectrum of 
activities of the viral RdRp and of its regulation can only be seen within the cell nucleus. As 
discussed before, and as shown in Fig 3.6, NS1 located in nucleus of transfected cells, while 
GD- and Ma NS1 proteins from recombinant viruses located predominantly in the cytoplasm 
of infected cells. This NS1 relocalization from nucleus to cytoplasm maybe one of possible 
reasons that explains why different effects of NS1 on RdRp activity between infected cells 
and uninfected cells were detected. It was suggested that the nuclear export signal (NES) of 
NS1 is masked by an inhibitory aa sequence adjacent to the NES in transfected cells while it 
could be unmasked by the specific interaction with another virus-specific protein (124). It can 
be assumed that the GD- and Ma NS segments enhance the replication and transcription 
activity of RdRp in infection but decrease its activity in in vitro RNP constitution 
experiments, which might be due to the unmasking effect in infected cells. In RNP 
constitution experiments, the retention of the NS1 protein in nucleus may lead to the decrease 
of the RdRp activity directly or indirectly. If it is true, it will be of great interest to identify the 
putative specific protein that interacts with the NS1 protein to unmask its NES and allows 
cztoplasmatic NS1 localisation. 
 
4.3.2. The effect of NS1 on the RdRp depends on the RNP complex 
The results shown in Fig 3.10 revealed that the NS1 effect on viral transcription and 
replication may depend on the fact whether the viral RNP complex represents the homology 
or a heterology complex . It is interesting to note that expression of the PR8 NS1 protein 
increases the polymerase activity of the PR8 RNP complex,.  It has been suggested that PR8 
NS1 protein can enhance polymerase and NP protein expression by increasing translation 
(138). However as the PR8 NS1 protein has no effect on the FPV and GD systems it seems as 
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though this is strain-specific. The speculation that the effect of NS1 on RNP activity is 
dependent on the virus strain is also supported by a study showing that NS1 proteins can only 
form complexes containing CPSF30 with cognate RNP complexes24 rather than RNP 
complexes of other viral strains (215).  
 
4.4. NS exchange also changes the RNP export patterns and this is correlated to the virus 
titer. 
The transport of viral RNP complexes was investigated using immunofluorescence, The 
results showed that the RNP localization of  the FPV wt and FPV NS GD viruses had a mostly 
cytoplasmic distribution, while FPV NS VN and FPV NS Ma showed a more nuclear RNP 
localization. This suggests that transport of the viral genome out of the nucleus was reduced 
for these viruses (Fig.3.6). The more rapid RNP export was found to correlate with higher 
virus titers An explanation for this could be that less efficient RNP export should lead to 
lower infectious titres by limiting RNPs available for packaging (228). NS2 can mediate RNP 
export by interaction with M1 protein. The aa comparison of NS2/NEP (Fig. 1C) shows that 
there are only two aa differences between the GD and Ma NS2/NEP protein sequences. 
Therefore, if NS2/NEP confers the demonstrated difference in RNP export, it should be based 
on this two aa difference, otherwise the RNP export of FPV NS GD should be similar to FPV 
NS Ma, while RNP export of FPV wt should be similar to that of FPV NS VN. In contrast,  
here data showed RNP export of FPV NS GD is stronger than FPV wt and that of FPV wt is 
stronger than FPV NS Ma and FPV NS VN. I was therefore unlikely that NS2/NEP is 
responsible for the observed differences. Further experiments need to be performed to 
investigate this.  
 
4.5. The ability to limit type 1 interferon response differs among the different NS1 
proteins and the IFN beta level is inversely correlated to virus titer. 
The influenza NS1 protein has been characterized as a type I IFN antagonist that is crucial for 
efficient viral replication by blocking interferon production and the anti-viral effects of IFN-
induced proteins, such as PKR and and 2'5'-oligoadenylate synthetase (OAS)/RNase L. My 
results showed that the NS segment exchange in an FPV genetic background altered IFN-beta 
production, and that IFN-beta levels were inversely correlated to the infectious virus titer. 
Since NS1 proteins of several diverse avian IAV strains were shown to have different 
inhibitory properties against IFN gene expression in mammalian cells (248), it can be 
assumed that the different innate immune response raised by the different NS reassortant 
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viruses in A549 cells are related to the difference of NS1 protein. However, as discussed 
before, the kinetics of the viral replication curves in type 1 deficient Vero cells showed no 
marked difference compared to MDCK cells. This indicates that type 1 interferon may not 
play the major role in inhibiting replication of the reassortant viruses and may only act as the 
indicator of host innate immune response. This assumption needs to be confirmed by 
investigations to determine whether the same amount of IFN-beta induced by the reassortant 
viruses can inhibit FPV wt replication to corresponding level as that the reassortant viruses 
reached. Wild type VN virus induces higher TNF-α levels than some human influenza A virus 
(249). In this reports, it was shown that VN NS alone in an A/WSN/33 (H1N1) background 
did not confer higher TNF-α level, but it rather depends on gene constellations like H5 
replication complex (NP/PA/PB1/PB2) or H5 surface proteins in addition to H5 matrix 
proteins (HA/NA/M). From this results, it can not be excluded that the different ability of our 
four NS segments to induce IFN-beta level also relies on the genetic background.  
 
4.6. The NS reassortants show different ability to induce apoptosis and the number of 
apoptotic cells is inversely correlated to virus titer. 
It is known that the NS1 protein is involved in the apoptosis during viral infection of host 
cells; however it is not clear whether it plays a pro- or anti-apoptotic role. The extent of 
apoptosis induced by the recombinant viruses was examined, and it was found that the FPV 
NS VN and FPV NS Ma viruses induced more apoptosis than the FPV wt and FPV NS GD 
viruses (Fig. 3.13).  The levels of apoptosis induced were found to be inversely correlated to 
the virus titers. Therefore a general trend was observed; infection with recombinant viruses in 
which the NS segment exchange resulted in lower titers induced higher levels of IFN-beta and 
cellular apoptosis compared to those viruses with higher titers. It is known that IFN can render 
cells more sensitive to apoptosis (198), but the relationship between viral 
replication/transcription and the anti-viral response is still not clear, including the type-1 
interferon response and apoptosis. PKR inhibition can affect the IFN response and viral RNA 
synthesis IV infection (125, 138, 150, 155, 250), and is also correlated to cell apoptosis in 
cancer (251). However, the result shows that PKR doesn’t seem to play a major role for the 
effects caused by NS segment reassortment (Fig. 8). It would be of interest in the future to 
investigate whether the differences in viral replication and transcription are the consequence 
of the host antiviral response or whether they are responsible for initiating the host response. 
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4.7. The effect of NS segment reassortment on virus propagation results from a 
summary of effects in multiple steps during the viral infection cycle. 
  FPVwt FPV NS GD FPV NS VN FPV NS Ma 
NS1 localization in 
transfected cells 
all in the 
nucleus 
all in the 
nucleus 
all in the nucleus all in the 
nucleus 
NS1 localization in 
infected cells 
most in 
the 
nucleus 
most in the 
cytoplasm 
some in the 
nucleus, some in 
the cytoplasm 
most in the 
cytoplasm 
NS1 and protein level 
(compared to FPV wt 
at 4h p.i.) 
1 1.27 1.32 1.92 
Transcription and 
replication compared 
to FPV wt ( at 4h.p.i.) 
mRNA: 1 
cRNA: 1 
vRNA:1 
(levels set 
to 1) 
mRNA: 3.5 
cRNA: 15 
vRNA:11 
(compared to 
FPV wt) 
mRNA: 1.2 
cRNA: 1.2 
vRNA:1.3 
(compared to 
FPV wt) 
mRNA: 1.3 
cRNA: 3.4 
vRNA: 2.2 
(compared to 
FPV wt) 
viral genome 
replication and 
nuclear export  
RNP export ++ +++ + + 
IFN beta leverl 
(36h.p.i.) 
17 IU/ml 10 IU/ml 11 IU/ml 37 IU/ml 
anti apoptosis (6h p.i.) +++ + + ++ 
host anti viral 
response 
apoptosis induction + + ++ +++ 
virus infectious titer 
(FFU/ml) 
106 107 105 105 
HA (HU/ml, at 24h 
p.i.) 
2560 5120 5120 1280 
viral propagation 
plaque size ++ +++ ++ + 
 
In summary, the NS1 protein is a small 26 kDa protein but it plays a very important and multi-
factorial role in the battle between the influenza virus and its host. Our results show that the 
exchange of NS segments can have a significant effect on the replicative ability and 
infectivity of the virus, and supports the notion that NS products are involved in many stages 
of the virus lifecycle; from replication, transcription and vRNP export to the counteraction of 
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the host response and induction of apoptosis. It is not possible to say which of these effects is 
the most important. This suggests that the effect of NS segment reassortment on virus 
replication and virulence is a summary effect and might depend on team work with other viral 
gene products. 
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Abbreviations 
aa     amino acids 
Amp.   ampicillin 
APS    ammonium persulfate 
AI     avian influenza 
AIV    avian influenza virus 
bp     base pairs 
BSA    bovine serum albumin 
°C     grade celcius 
cm    centimetre 
DAG    diacylglycerol 
ddH2O   deionized distilled water 
DMEM   Dulbecco's Modified Eagle's medium 
DMSO   dimethylsulfoxide 
DNA    deoxyribonucleic acid 
dNTP    deoxynucleoside triphosphate 
DTT    dithiothreitol 
EDTA    ethylenediamine tetraacetic acid 
ECL    enhanced chemoluminiscence 
eIF2    eukaryotic translation initiation factor 2 
ERK    extracellular signal regulated kinase 
et al.    et alii (and others) 
FCS    fetal calf serum 
FFU   foci forming unit(s) 
FPV    fowl plague virus 
g     gram 
h     hour(s) 
HA    hemagglutinin 
HEPES   N-2-hydroxyethylpiperazine 
HPAIV   highly pathogenic avian influenza virus 
IFA    indirect immunofluoresces assay 
IFN    interferon 
IRF3    IFN regulatory factor 3 
kb     kilobase pairs 
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LPAIV   lowly pathogenic avian influenza virus 
M     molar 
M1    matrixprotein 
M2    ion channel protein 
MAPK   mitogen-activated protein kinase 
MAPKK   MAPK kinase 
MAPKKK   MAPKK kinase 
MEK    MAPK/ERK activated kinase 
MEKK   MAPK/ERK activated kinase Kinase 
MCD   methyl-ß-cyclodextrin 
mg    milligram 
min    minute(s) 
ml     milliliter 
mM    millimolar 
m.o.i.    multiplicity of infection 
mRNA   messenger RNA 
NA    neuraminidase 
NCR    noncoding region(s) 
NEP/NS2   nuclear export factor 
NES    nuclear export signal 
NLS    nuclear location signal 
NP    nucleocapsidprotein 
NPC    nuclear pore complex 
NS1    nonstructural protein 
ng     nanogram 
nt     nucleotide(s) 
OD    optical density 
PA    subunit of RDRP 
PAGE    polyacrylamide gel eletrophoresis 
PB1    subunit of RDRP 
PB2    subunit of RDRP 
PBS    phosphate buffered saline 
PCR    polymerase chain reaction 
PFU    plaque forming unit(s) 
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p.i.    post infection 
PKR    dsRNA activated protein kinase 
pmol    picomolar 
PolyA    polyadenylic acid 
Pol I    RNA polymerase I 
p.t.    post transfection 
RDRP    RNA-dependent RNA-polymerase 
RNA    ribonucleic acid 
RNPs    ribonucleoproteins 
rpm    rounds per minute 
RSK    ribosomal S6 kinase 
RTK   receptor tyrosine kinase 
s     second(s) 
SDS    sodium dodecyl sulfate 
TEMED   N,N,N',N'-tetramethylethylenediamine 
TPA   12-O-Tetradecanoylphorbol 13-acetate 
Tris    tris-hydroxymethylaminomethane 
Tween 20   polyoxyethylenesorbiten monolaurate 
V     volt 
vRNA    viral RNA 
v/v    volume percentage 
w/v    weight percentage 
µg     microgram 
µl     microliter 
µM    micromolar 
